



---

# MMWR<sup>TM</sup>

## Morbidity and Mortality Weekly Report

---

Recommendations and Reports

December 8, 2006 / Vol. 55 / No. RR-16

---

### **A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States**

**Recommendations of the Advisory  
Committee on Immunization Practices (ACIP)  
Part II: Immunization of Adults**

**INSIDE: Continuing Education Examination**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION**

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Title]. *MMWR* 2006;55(No. RR-#):[inclusive page numbers].

#### Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH  
*Director*

Tanja Popovic, MD, PhD  
*(Acting) Chief Science Officer*

James W. Stephens, PhD  
*(Acting) Associate Director for Science*

Steven L. Solomon, MD  
*Director, Coordinating Center for Health Information and Service*

Jay M. Bernhardt, PhD, MPH  
*Director, National Center for Health Marketing*

Judith R. Aguilar  
*(Acting) Director, Division of Health Information Dissemination (Proposed)*

#### Editorial and Production Staff

Frederic E. Shaw, MD, JD  
*(Acting) Editor, MMWR Series*

Suzanne M. Hewitt, MPA  
*Managing Editor, MMWR Series*

Teresa F. Rutledge  
*Lead Technical Writer-Editor*

Jeffrey D. Sokolow, MA  
*Project Editor*

Beverly J. Holland  
*Lead Visual Information Specialist*

Lynda G. Cupell  
Malbea A. LaPete  
*Visual Information Specialists*

Quang M. Doan, MBA  
Erica R. Shaver  
*Information Technology Specialists*

#### Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman

Virginia A. Caine, MD, Indianapolis, IN

David W. Fleming, MD, Seattle, WA

William E. Halperin, MD, DrPH, MPH, Newark, NJ

Margaret A. Hamburg, MD, Washington, DC

King K. Holmes, MD, PhD, Seattle, WA

Deborah Holtzman, PhD, Atlanta, GA

John K. Iglehart, Bethesda, MD

Dennis G. Maki, MD, Madison, WI

Sue Mallonee, MPH, Oklahoma City, OK

Stanley A. Plotkin, MD, Doylestown, PA

Patricia Quinlisk, MD, MPH, Des Moines, IA

Patrick L. Remington, MD, MPH, Madison, WI

Barbara K. Rimer, DrPH, Chapel Hill, NC

John V. Rullan, MD, MPH, San Juan, PR

Anne Schuchat, MD, Atlanta, GA

Dixie E. Snider, MD, MPH, Atlanta, GA

John W. Ward, MD, Atlanta, GA

## CONTENTS

|  |      |
|--|------|
| Introduction .....   | 2    |
| Methods .....  | 3    |
| Major Updates to the Recommendations .....                   | 3    |
| Background .....   | 3    |
| Clinical Features and Natural History of HBV Infection ..... | 3    |
| Interpretation of Serologic Markers of HBV Infection .....   | 4    |
| Epidemiology of HBV Infection .....                          | 5    |
| Prophylaxis Against HBV Infection .....                      | 8    |
| Hepatitis B Vaccine .....                                    | 8    |
| Hepatitis B Immune Globulin .....                            | 9    |
| Adult Vaccination Schedules and Results of Vaccination ..... | 10   |
| Preexposure Vaccination .....                                | 10   |
| Postexposure Prophylaxis .....                               | 12   |
| Vaccine Safety .....   | 12   |
| Vaccine Reactogenicity .....                                 | 12   |
| Adverse Events .....   | 12   |
| Contraindications and Precautions .....                      | 13   |
| Implementation Barriers and Rationale                        |      |
| for New Recommendations .....                                | 13   |
| Recommendations and Implementation Strategies                |      |
| for Hepatitis B Vaccination of Adults .....                  | 15   |
| Recommendations .....  | 15   |
| Implementation Strategies .....                              | 16   |
| Acknowledgments .....  | 18   |
| References .....   | 18   |
| Appendices .....   | 26   |
| Continuing Education Activity .....                          | CE-1 |

#### Disclosure of Relationship

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

# A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States

## Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults

Prepared by  
Eric E. Mast, MD<sup>1</sup>  
Cindy M. Weinbaum, MD<sup>1</sup>  
Anthony E. Fiore, MD<sup>1</sup>  
Miriam J. Alter, PhD<sup>1</sup>  
Beth P. Bell, MD<sup>1</sup>  
Lyn Finelli, DrPH<sup>1</sup>  
Lance E. Rodewald, MD<sup>2</sup>  
John M. Douglas, Jr., MD<sup>3</sup>  
Robert S. Janssen, MD<sup>4</sup>  
John W. Ward, MD<sup>1</sup>

<sup>1</sup>Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed)

<sup>2</sup>Immunization Services Division, National Center for Immunization and Respiratory Diseases (proposed)

<sup>3</sup>Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed)

<sup>4</sup>Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed)

### Summary

*Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, including cirrhosis of the liver, liver cancer, liver failure, and death. In adults, ongoing HBV transmission occurs primarily among unvaccinated persons with behavioral risks for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic HBV infection.*

*This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]:1–33).*

*In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immunodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV*

*infection receive care, health-care providers should inform all patients about the health benefits of vaccination, including risks for HBV infection and persons for whom vaccination is recommended, and vaccinate adults who report risks for HBV infection and any adults requesting protection from HBV infection. To promote vaccination in all settings, health-care providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine clinical services, not require acknowledgment of an HBV infection risk factor for adults to receive vaccine, and use available reimbursement mechanisms to remove financial barriers to hepatitis B vaccination.*

The material in this report originated in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), Kevin A. Fenton, MD, PhD, Director; the Division of Viral Hepatitis, John W. Ward, MD, Director; the Division of STD Prevention, John M. Douglas, Jr., MD, Director; and the Division of HIV/AIDS Prevention, Robert S. Janssen, MD, Director; the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; and the Immunization Services Division, Lance E. Rodewald, MD, Director.

**Corresponding preparer:** Eric E. Mast, MD, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), 1600 Clifton Road, NE, MS G-37, Atlanta, GA 30333. Telephone: 404-718-8500; Fax: 404-718-8595; E-mail: emast@cdc.gov.

## Introduction

Hepatitis B is a disease caused by the hepatitis B virus (HBV), which is transmitted through percutaneous (i.e., puncture through the skin) or mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or body fluids. HBV can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. Persons with chronic infection also serve as the main reservoir for continued HBV transmission. Although chronic infection is more likely to develop in persons infected as infants or young children, rates of new infection and acute disease are highest among adults.

Hepatitis B vaccination is the most effective measure to prevent HBV infection and its consequences. Since recommendations for hepatitis B vaccination were first issued in 1982, a comprehensive strategy to eliminate HBV transmission in the United States has evolved (1–5). This strategy includes 1) universal vaccination of infants beginning at birth, 2) prevention of perinatal HBV infection through routine screening of all pregnant women for hepatitis B surface antigen (HBsAg) and postexposure immunoprophylaxis of infants born to HBsAg-positive women or to women with unknown HBsAg status, 3) vaccination of all children and adolescents who were not vaccinated previously, and 4) vaccination of previously unvaccinated adults at risk for HBV infection (Box 1).

To date, immunization strategies for infants, children, and adolescents have been implemented with considerable success. Recent estimates indicate that approximately 95% of pregnant women are tested for HBsAg and that case management has been effective in ensuring high levels of initiation and completion of postexposure immunoprophylaxis among infants born to HBsAg-positive women (6). Hepatitis B vaccine has been integrated successfully into the childhood vaccination schedule, and infant vaccination coverage levels now are equivalent to those of other vaccines in the childhood

schedule (7). Vaccination coverage among adolescents also has increased substantially; preliminary data from 2003 indicated that approximately 50%–60% of adolescents aged 13–15 years have records indicating vaccination (with 3 doses) against hepatitis B (8). During 1990–2005, incidence of acute hepatitis B in the United States declined 78%. The greatest decline (96%) occurred among children and adolescents, coincident with an increase in hepatitis B vaccination coverage. This success can be attributed in part to the established infrastructure for vaccine delivery to children and to federal support for perinatal hepatitis B prevention programs.

Among adults, ongoing HBV transmission occurs primarily among unvaccinated adults with risk behaviors for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic HBV infection. During 2000–2004, self-reported hepatitis B vaccination coverage among adults at risk for HBV infection increased from 30% to 45% (9); this increase in vaccination coverage likely contributed to the 35% decline in acute hepatitis B incidence that occurred during this period (from 3.7 to 2.4 per 100,000 population). However, incidence of acute hepatitis B remains highest among adults, who accounted for approximately 95% of an estimated 51,000 new HBV infections in 2005. Although acceptance of vaccination is high among adults offered vaccination (10), the low adult vaccination coverage reflects the lack of hepatitis B vaccination services in settings in which a high proportion of adults have risk factors for HBV infection (e.g., sexually transmitted disease [STD]/human immunodeficiency virus [HIV] testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities) and missed opportunities to vaccinate adults at risk for HBV infection in primary care and specialty medical settings. Although hepatitis B incidence among adults is expected to continue to decline during the next decade as successive cohorts of persons vaccinated in infancy, childhood, and adolescence reach adulthood, new implementation strategies are needed to protect unvaccinated adults at risk for HBV infection.

This report provides updated guidance from the Advisory Committee on Immunization Practices (ACIP) to increase hepatitis B vaccination coverage among adults. It includes recommendations regarding which adults should receive hepatitis B vaccine and outlines implementation strategies to ensure that those adults are vaccinated. The first part of this statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (11).

### BOX 1. Immunization strategy to eliminate transmission of hepatitis B virus (HBV) in the United States

- Universal vaccination of infants beginning at birth
- Prevention of perinatal HBV infection through
  - routine screening of all pregnant women for hepatitis B surface antigen (HBsAg), and
  - immunoprophylaxis of infants born to HBsAg-positive women or to women with unknown HBsAg status
- Routine vaccination of previously unvaccinated children and adolescents
- Vaccination of previously unvaccinated adults at risk for HBV infection

## Methods

In response to continuing low rates of hepatitis B vaccination among adults at risk for HBV infection, ACIP's Hepatitis Vaccines Work Group met multiple times during October 2004–September 2005 to review previous guidelines and make recommendations for improving vaccination coverage in adults. The work group examined the progress made since 1991 in implementing the U.S. strategy to eliminate HBV transmission (e.g., vaccination coverage data and hepatitis B disease rates), surveillance data on missed opportunities for hepatitis B vaccination among adults with acute hepatitis B, and results of cost-effectiveness analyses. In addition, demonstration projects conducted in settings in which a high proportion of clients were at risk for HBV infection identified the components of successful adult hepatitis B vaccination programs and ongoing challenges to implementing adult hepatitis B vaccination.

In January 2005, the proposed recommendations were posted online for public comment. In May 2005, CDC convened a meeting of external consultants, including researchers, physicians, state and local public health professionals, immunization program directors, and directors of viral hepatitis, STD, and HIV/AIDS prevention programs, to obtain input into the draft recommendations and consider the feasibility of the recommended strategies. In October 2005, the revised recommendations were approved by ACIP.

## Major Updates to the Recommendations

This report updates ACIP recommendations published previously for hepatitis B vaccination of adults (3). The primary changes from previous recommendations are as follows:

- In settings in which a high proportion of persons are likely to be at risk for HBV infection (e.g., STD/HIV testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all adults who have not completed the vaccine series.
- In primary care and specialty medical settings, ACIP recommends implementation of standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine services. To ensure vaccination of adults at risk for HBV infection who have not completed the vaccine series, ACIP recommends the following implementation strategies:

- Provide information to all adults regarding the health benefits of hepatitis B vaccination, including risk factors for HBV infection and persons for whom vaccination is recommended.
- Help all adults assess their need for vaccination by obtaining a history that emphasizes risks for sexual transmission and percutaneous or mucosal exposure to blood.
- Vaccinate all adults who report risks for HBV infection.
- Vaccinate all adults requesting protection from HBV infection, without requiring them to acknowledge a specific risk factor.

## Background

### Clinical Features and Natural History of HBV Infection

HBV is a 42-nm DNA virus classified in the *Hepadnaviridae* family. The liver is the primary site of HBV replication. After a susceptible person is exposed, the virus enters the liver via the bloodstream; no evidence exists indicating that the virus replicates at mucosal surfaces. HBV infection can produce either asymptomatic or symptomatic infection. The average incubation period is 90 days (range: 60–150 days) from exposure to onset of jaundice and 60 days (range: 40–90 days) from exposure to onset of abnormal serum alanine aminotransferase (ALT) levels (12,13).

The onset of acute disease typically is insidious. Infants, children aged <5 years, and immunosuppressed adults with newly acquired HBV infection typically are asymptomatic, whereas 30%–50% of children aged ≥5 years and adults have initial clinical signs or symptoms (14). When present, clinical symptoms and signs can include anorexia, malaise, nausea, vomiting, abdominal pain, and jaundice. Extrahepatic manifestations of disease (e.g., skin rashes, arthralgias, and arthritis) also can occur (15). The fatality rate among persons with reported cases of acute hepatitis B is 0.5%–1.0%, with the highest rates in adults aged >60 years; however, because a substantial number of infections are asymptomatic and therefore are not reported, the overall fatality rate among all persons with HBV infection likely is lower (16).

Approximately 95% of primary infections in adults with normal immune status are self-limited, with elimination of virus from blood and subsequent lasting immunity to reinfection. Chronic infection occurs in <5% of infected persons aged ≥5 years, approximately 30% of infected children aged <5 years, and approximately 90% of infected infants, with continuing viral replication in the liver and persistent viremia (14,17–19).

Primary infections become chronic more frequently in immunosuppressed persons (e.g., hemodialysis patients and persons with HIV infection) (19,20) and persons with diabetes (21). Overall, approximately 25% of persons who become chronically infected during childhood and 15% of those who become chronically infected after childhood die prematurely from cirrhosis or liver cancer; the majority remain asymptomatic until onset of cirrhosis or end-stage liver disease (22).

No specific treatment exists for acute hepatitis B; supportive care is the mainstay of therapy. Persons who have chronic HBV infection require medical evaluation and regular monitoring (23–25). Therapeutic agents approved by the Food and Drug Administration (FDA) for treatment of chronic hepatitis B can achieve sustained suppression of HBV replication and remission of liver disease in certain persons (24). Periodic screening with ultrasonography and alpha-fetoprotein has been demonstrated to enhance early detection of hepatocellular carcinoma (HCC) (25). Certain chronically infected persons with HCC have experienced long-term survival after resection of small hepatocellular carcinomas, and persons who were screened had HCC detected at an earlier stage and had a substantial survival advantage compared with historical controls (25); however, data from controlled studies are lacking. Guidance for the diagnosis and management of hepatitis B is available (26).

## Interpretation of Serologic Markers of HBV Infection

Antigens and antibodies associated with HBV infection include HBsAg and antibody to HBsAg (anti-HBs), hepatitis B core antigen (HBcAg) and antibody to HBcAg (anti-HBc), and hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). At least one serologic marker is present during each of the different phases of HBV infection (13,27). The serologic markers typically used to differentiate between acute, resolving, and chronic infection are HBsAg, anti-HBc, and anti-HBs (Table 1). HBeAg and anti-HBe screening typically is used for the management of patients with chronic infection. Serologic assays are available commercially for all markers except HBcAg because no free HBcAg circulates in blood.

The presence of a confirmed HBsAg-positive result in serum indicates active HBV infection. All HBsAg-positive persons should be considered infectious. In newly infected persons, HBsAg is the only serologic marker detected during the first 3–5 weeks after infection. The average time from exposure to detection of HBsAg is 30 days (range: 6–60 days) (12,13). Highly sensitive single-sample nucleic acid tests can detect HBV DNA in the serum of an infected person 10–20 days before detection of HBsAg (28). Transient HBsAg positivity has been reported for up to 18 days after hepatitis B vaccination and is clinically insignificant (29,30).

**TABLE 1. Typical interpretation of serologic test results for hepatitis B virus infection**

| Serologic marker |                 |                           |           | Interpretation   |
|------------------|-----------------|---------------------------|-----------|--|
| HBsAg*           | Total anti-HBc† | IgM <sup>§</sup> anti-HBc | Anti-HBs¶ |  |
| –**              | –               | –                         | –         | Never infected   |
| +††§§            | –               | –                         | –         | Early acute infection; transient (up to 18 days) after vaccination   |
| +                | +               | +                         | –         | Acute infection  |
| –                | +               | +                         | + or –    | Acute resolving infection  |
| –                | +               | –                         | +         | Recovered from past infection and immune   |
| +                | +               | –                         | –         | Chronic infection  |
| –                | +               | –                         | –         | False-positive (i.e., susceptible); past infection; “low-level” chronic infection;¶¶ or passive transfer of anti-HBc to infant born to HBsAg-positive mother |
| –                | –               | –                         | +         | Immune if concentration is ≥10 mIU/mL after vaccine series completion;*** passive transfer after hepatitis B immune globulin administration                  |

\* Hepatitis B surface antigen.

† Antibody to hepatitis B core antigen.

§ Immunoglobulin M.

¶ Antibody to HBsAg.

\*\* Negative test result.

†† Positive test result.

§§ To ensure that an HBsAg-positive test result is not a false-positive, samples with reactive HBsAg results should be tested with a licensed neutralizing confirmatory test if recommended in the manufacturer's package insert.

¶¶ Persons positive only for anti-HBc are unlikely to be infectious except under unusual circumstances in which they are the source for direct percutaneous exposure of susceptible recipients to large quantities of virus (e.g., blood transfusion or organ transplant).

\*\*\* Milli-international units per milliliter.

Anti-HBc appears at the onset of symptoms or liver-test abnormalities in acute HBV infection and persists for life. Acute or recently acquired infection can be distinguished by the presence of the immunoglobulin M (IgM) class of anti-HBc, which is detected at the onset of acute hepatitis B and persists for up to 6 months if the disease resolves. In patients who have chronic HBV infection, IgM anti-HBc can persist during viral replication at low levels that typically are not detectable by assays used in the United States. However, persons with exacerbations of chronic infection can test positive for IgM anti-HBc (31). Using IgM anti-HBc testing for diagnosis of acute hepatitis B should be limited to persons for whom clinical evidence of acute hepatitis or an epidemiologic link to a case has been identified because the positive predictive value of this test is low in asymptomatic persons.

In persons who recover from HBV infection, HBsAg is eliminated from the blood, and anti-HBs develops, typically within 3–4 months. The presence of anti-HBs typically indicates immunity from HBV infection. Infection or immunization with one serotype of HBV confers immunity to all serotypes. In addition, anti-HBs can be detected for several months after hepatitis B immune globulin (HBIG) administration. Persons who recover from natural infection typically will be positive for both anti-HBs and anti-HBc, whereas persons who respond to hepatitis B vaccine have only anti-HBs. In persons who become chronically infected, HBsAg and anti-HBc persist, typically for life. HBsAg will become undetectable in approximately 0.5%–2% of persons with chronic infection yearly; anti-HBs will occur in the majority of these persons (32–35).

In certain persons, the only HBV serologic marker detected in serum is anti-HBc. Isolated anti-HBc can be detected after HBV infection in persons who have recovered but whose anti-HBs levels have waned. Certain chronically infected persons with anti-HBc alone have circulating HBsAg not detectable by commercial serology. HBV DNA has been detected in the blood of <10% of persons with isolated anti-HBc (36,37). These persons are unlikely to be infectious except under circumstances in which they are a source for direct percutaneous exposure of susceptible recipients to substantial quantities of virus (e.g., through blood transfusion or organ transplantation) (38). An isolated anti-HBc result also can be a false-positive. Typically, the frequency of isolated anti-HBc relates directly to the prevalence of HBV infection in the population. In populations with a high prevalence of HBV infection, isolated anti-HBc likely indicates previous infection, with loss of anti-HBs. For persons in populations with a low prevalence of HBV infection, isolated anti-HBc is found in approximately 10%–20% of persons with serologic markers of HBV infection (37) and often represents a false-positive reaction; the majority of these persons have a primary anti-

HBs response after a 3-dose series of hepatitis B vaccine (39,40).

HBeAg can be detected in the serum of persons with acute or chronic HBV infection. The presence of HBeAg correlates with high levels of viral replication (i.e., HBV DNA levels typically of  $10^7$ – $10^9$  IU/mL, indicating high infectivity) (41,42). Loss of HBeAg correlates with low levels (i.e., HBV DNA levels of  $<10^5$  IU/mL) of replicating virus, although certain HBeAg-negative persons have HBV DNA levels up to  $10^8$ – $10^9$  IU/mL (43). A mutation in the precore region of the HBV genome has been identified in HBeAg-negative persons with high HBV DNA levels (44,45).

## Epidemiology of HBV Infection

HBV is transmitted by percutaneous or mucosal exposure to infectious blood or body fluids. Although HBsAg has been detected in multiple body fluids, only serum, semen, and saliva have been demonstrated to be infectious (46,47). HBV is concentrated most highly in serum, with lower concentrations in semen and saliva. All HBsAg-positive persons are infectious, but those who are also HBeAg positive are more infectious because their blood contains high titers of HBV (typically HBV DNA levels of  $10^7$ – $10^9$  IU/mL) (41,42). HBV is comparatively stable in the environment and remains viable for  $\geq 7$  days on environmental surfaces at room temperature (48). HBV DNA at concentrations of  $10^2$ – $10^3$  IU/mL can be present on environmental surfaces in the absence of any visible blood and still cause transmission (48,49).

For adults, the two primary sources of HBV infection are sexual contact and percutaneous exposure to blood. Person-to-person transmission of HBV also can occur in settings involving nonsexual interpersonal contact over an extended period (e.g., among household contacts of a person with chronic HBV infection and developmentally disabled persons living in a long-term-care facility).

HBV is transmitted efficiently by sexual contact among heterosexuals and among MSM. Risk factors associated with sexual transmission among heterosexuals include having unprotected sex with an infected partner, having unprotected sex with more than one partner, and history of another STD. Risk factors associated with sexual transmission among MSM include having multiple sex partners, history of another STD, and anal intercourse.

Percutaneous transmission of HBV can occur from receipt of blood transfusion or organ or tissue transplant from an infectious donor; injection-drug use, including sharing of injection-preparation equipment; and frequent exposure to blood or needles among health-care workers. In the United States, donor selection procedures and routine testing of

donors have made transmission of HBV via transfusion of whole blood and blood components a rare occurrence (50,51). Persons with hemophilia who received plasma-derived clotting factor concentrates were previously at high risk for HBV infection, but such transmission has been eliminated through viral inactivation procedures and use of recombinant clotting factor concentrates. Among persons with bleeding disorders treated at U.S. hemophilia treatment centers during 1998–2002, no infections with viral hepatitis, including HBV, were attributable to blood products received during that time (52). Outbreaks of HBV infection from exposure to contaminated equipment used for therapeutic injections and other health-care–related procedures, tattooing, and acupuncture also have been reported, although such exposures among patients with acute hepatitis B are reported rarely (53–57). In the majority of cases, transmission resulted from noncompliance with aseptic techniques for administering injections and recommended infection-control practices designed to prevent cross-contamination of medical equipment and devices. No infections have been demonstrated in susceptible persons who had oral mucous membrane exposure to HBsAg-positive saliva, but transmission has occurred through a human bite and has been demonstrated in animals by subcutaneous inoculation of saliva (46,58–60).


Persons living with chronically infected persons are at risk for HBV infection through percutaneous or mucosal exposures to blood or infectious body fluids (e.g., sharing a toothbrush or razor, contact with exudates from dermatologic lesions, or contact with HBsAg-contaminated surfaces). Persons with chronic HBV infection also can transmit HBV in other settings (e.g., schools, child care centers, or facilities for developmentally disabled persons), especially if they behave aggressively or have medical problems (e.g., exudative dermatitis or open skin lesions) that increase the risk for exposure to blood or serous secretions.

### Adults at Risk for HBV Infection

In the United States in 2005, the highest incidence of acute hepatitis B was among adults aged 25–45 years (Figure 1). Approximately 79% of newly acquired cases of hepatitis B are associated with high-risk sexual activity or injection-drug use; other known exposures (i.e., occupational, household, travel, and health-care–related) together account for 5% of new cases, and 16% deny a specific risk factor for infection (61; CDC, unpublished data, 2001–2005).

**Adults at risk for infection by sexual exposure.** The most common source of HBV infection among adults in the United States is sexual contact. Heterosexual transmission accounts for approximately 39% of new HBV infections among adults,

**FIGURE 1. Reported incidence\* of acute hepatitis B, by age group and sex — United States, 2005**



\* Per 100,000 population.

and transmission among MSM accounts for approximately 24% (CDC, unpublished data, 2001–2005). Serologic evidence of HBV infection (i.e., anti-HBc positive) has ranged from 10% to 40% among adults seeking treatment in STD clinics (62–64) and from 10% to 25% among MSM aged <30 years (65; CDC, unpublished data, 1999–2000). Follow-up studies identified HBV infection in 20%–42% of susceptible heterosexual partners of persons with acute hepatitis B (66–68). Among susceptible heterosexual spouses of persons with chronic HBV infection, the seroprevalence of HBV infection ranged from 25% to 59% (69–71).

**Injection-drug users.** IDUs account for approximately 16% of new HBV infections in the United States (CDC, unpublished data, 2001–2005). Incidence of HBV infection among unvaccinated IDUs is high, ranging from 10 to 31 per 100 person-years (72–74). Risk for HBV transmission increases with the number of years of drug use and is associated with frequency of injection and with sharing of drug-preparation equipment (e.g., cottons, cookers, and rinse water), independent of syringe sharing (73,75).

In a study of the seroprevalence of HBV infection among IDUs admitted to drug treatment in six U.S. cities, 64% (range: 50%–81%) had serologic evidence of HBV infection, and seroprevalence increased with age (76). Studies of street-recruited IDUs (77,78) and female IDUs (79) have iden-

tified similar prevalence of HBV infection, whereas a lower prevalence (25%) was found in a study of young IDUs (aged 18–30 years) (74). Chronic HBV infection has been identified in 3.1% of IDUs in a detention setting (77) and 7.1% of IDUs with HIV coinfection (80).

**Household contacts of persons with chronic HBV infection.** Seroprevalence of HBV infection among susceptible household contacts of persons with chronic infection has varied, ranging from 14% to 60% (69,71,81–85). The risk for infection is highest among sex partners of, and children living with, a person with chronic HBV infection in a household or extended family setting (83–85).

**Developmentally disabled persons in long-term-care facilities.** Developmentally disabled persons in residential and nonresidential facilities historically have had high rates of HBV infection (86,87), but the prevalence of infection has declined substantially since the implementation of routine hepatitis B vaccination in these settings (88,89). Nonetheless, because HBsAg-positive persons reside in such facilities, clients and staff continue to be at risk for infection.

**Persons at risk for occupational exposure to HBV.** Before hepatitis B vaccination was widely implemented, HBV infection was recognized as a common occupational hazard among persons who were exposed to blood while caring for patients or working in laboratories (90,91). Since then, routine hepatitis B vaccination of health-care workers and use of standard precautions to prevent exposure to bloodborne pathogens have made HBV infection a rare event in these populations (92–94). Since the mid-1990s, the incidence of HBV infection among health-care workers has been lower than that among the general population (94). Public safety workers with exposures to blood also might be at risk for HBV infection (95–97); however, the prevalence of HBV infection in occupational groups such as police officers, firefighters, and corrections officers generally does not differ from that in the general population when adjusted for race and age (97), and infection is associated most often with nonoccupational risk factors (97,98). No increased risk for occupationally acquired HBV infection has been documented in workers exposed infrequently to blood or body fluids (e.g., ward clerks, dietary workers, maintenance workers, housekeeping personnel, teachers, and persons employed in day care settings) (91).

**Hemodialysis patients.** Since the initiation of strict infection-control practices and hepatitis B vaccination, the rate of HBV infection among patients undergoing hemodialysis has declined approximately 95% (99,100). Nonetheless, repeated outbreaks of HBV infection among unvaccinated patients underscore the continued risk for infection in this population (101).

**Persons with chronic liver disease.** Persons with chronic liver disease are not at increased risk for HBV infection unless they have percutaneous or mucosal exposure to infectious blood or body fluids. Furthermore, studies of the outcomes of acute hepatitis B among patients with chronic liver disease provide little evidence that acute hepatitis B increases their risk for an acute liver failure. However, concurrent chronic HBV infection might increase the risk for progressive chronic liver disease in HCV-infected patients (102).

**Travelers to HBV-endemic regions.** Short-term travelers to regions in which HBV infection is of high or intermediate endemicity (Box 2) typically are at risk for infection only through exposure to blood in medical, health-care, or disaster-relief activities; receipt of medical care that involves parenteral exposures; or sexual activity or drug use (103). Infection rates of 2%–5% per year among persons working in such regions for  $\geq 6$  months have been reported (104,105).

**HIV-positive persons.** Published data on the overall prevalence of HBV and HIV coinfection in the United States are

**BOX 2. Geographic regions\* with intermediate† and high‡ hepatitis B virus endemicity**

**Africa:** all countries

**East Asia:** all countries

**Eastern Europe and Northern Asia:** all countries except Hungary

**South Asia:** all countries except Sri Lanka

**Southeast Asia:** all countries

**Australia and the South Pacific:** all countries and territories except Australia and New Zealand

**Middle East:** all countries except Cyprus

**Western Europe:** Greece, Malta, Portugal, and Spain and indigenous populations of Greenland

**North America:** Alaska Natives and indigenous populations of Northern Canada

**Central America:** Belize, Guatemala, Honduras, and Panama

**South America:** Argentina, Bolivia, Brazil, Ecuador, Guyana, Suriname, Venezuela, and the Amazonian areas of Colombia and Peru

**Caribbean:** Antigua and Barbuda, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Puerto Rico, St. Kitts and Nevis, St. Lucia, St. Vincent and Grenadines, Trinidad and Tobago, and Turks and Caicos

\* A complete list of countries in each region is available at <http://www.cdc.gov/travel/destinat.htm>.

† Hepatitis B surface antigen (HBsAg) prevalence of 2%–7%.

‡ HBsAg prevalence of  $\geq 8\%$ .


limited. Studies of certain subgroups have identified prevalence of previous or current HBV infection of 45% in HIV-infected MSM aged 22–29 years (CDC, unpublished data, 1998–2000), 24% in adolescent HIV-infected males (106), and 43% in HIV-infected women, including 76% among HIV-infected female IDUs (79). Chronic HBV infection has been identified in 6%–14% of HIV-positive persons from Western Europe and the United States, including 9%–17% of MSM, 7%–10% of IDUs, and 4%–6% of heterosexuals (107).

The course of HBV infection can be modified in the presence of HIV, with a lower incidence of jaundice and a higher incidence of chronic HBV infection (20,108,109). Limited data also indicate that HIV-infected patients with chronic HBV infection have an increased risk for liver-related mortality and morbidity (110).

### Incidence of Acute Hepatitis B


During 1990–2005, the overall incidence of reported acute hepatitis B declined 78%, from 8.5 to 1.9 per 100,000 population (Figure 2), and the estimated number of new HBV infections, after adjusting for underreporting and asymptomatic infections, declined from approximately 232,000 to approximately 51,000 infections (CDC, unpublished data, 1990–2005). Among children and adolescents aged <19 years, incidence declined 96%, from 2.4 to 0.1 per 100,000 population. Among adults aged ≥19 years, incidence declined 76%, from 9.9 to 2.4 per 100,000 population, and racial/ethnic disparities in incidence were nearly eliminated for Asians/Pacific Islanders, American Indians/Alaska Natives, and Hispanics (Figure 3). Incidence also declined substantially among blacks aged ≥19 years during this period, from 19.7 to 4.2 per 100,000 population; however, in 2005, incidence among blacks remained nearly three times higher than that among other racial/ethnic populations. After leveling during 1999–

**FIGURE 2. Reported incidence\* of acute hepatitis B, by age group — United States, 1990–2005**



\* Per 100,000 population.

**FIGURE 3. Reported incidence\* of acute hepatitis B among persons aged ≥19 years, by race/ethnicity — United States, 1990–2005**



\* Per 100,000 population.

2002, acute hepatitis B incidence among adults decreased 35% during 2002–2005, from 3.7 to 2.4 per 100,000 population (CDC, unpublished data, 2006). In 2005, the highest incidence of acute hepatitis B occurred among persons aged 25–44 years.

### Prevalence of HBV Infection


During 1988–1994, the overall age-adjusted prevalence of HBV infection (including previous or chronic infection) in the U.S. population was 4.9%, and the prevalence of chronic infection was 0.4% (111). Persons who have immigrated to the United States from countries in which HBV is endemic (Box 2, Figure 4) are affected disproportionately by chronic HBV infection; in particular, the majority of chronic HBV infections in the United States are among Asians/Pacific Islanders (112–114). The prevalence of chronic HBV infection among persons immigrating to the United States from Central and Southeast Asia, the Middle East, and Africa varies (range: 5%–15%) and reflects the patterns of HBV infection in the countries and regions of origin. During 1994–2003, approximately 40,000 immigrants with chronic HBV infection were admitted annually to the United States for permanent residence (115; CDC, unpublished data, 2005).

## Prophylaxis Against HBV Infection

### Hepatitis B Vaccine

Hepatitis B vaccine is available as a single-antigen formulation and also in fixed combination with other vaccines. Two

FIGURE 4. Geographic distribution of chronic hepatitis B virus (HBV) infection — worldwide, 2005\*



\* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data and might not reflect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might vary within countries by subpopulation and locality.

single-antigen vaccines are available in the United States: Recombivax HB<sup>®</sup> (Merck & Co., Inc., Whitehouse Station, New Jersey) and Engerix-B<sup>®</sup> (GlaxoSmithKline Biologicals, Rixensart, Belgium). Of the three licensed combination vaccines, one (Twinrix<sup>®</sup> [GlaxoSmithKline Biologicals, Rixensart, Belgium]) is used for vaccination of adults and two (Comvax<sup>®</sup> [Merck & Co., Inc., Whitehouse Station, New Jersey] and Pediarix<sup>®</sup> [GlaxoSmithKline Biologicals, Rixensart, Belgium]) are used for vaccination of infants and young children. Twinrix contains recombinant HBsAg and inactivated hepatitis A virus. Comvax contains recombinant HBsAg and *Haemophilus influenzae* type b (Hib) polyribosylribitol phosphate conjugated to *Neisseria meningitidis* outer membrane protein complex. Pediarix contains recombinant HBsAg, diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), and inactivated poliovirus (IPV).

HBsAg is the antigen used for hepatitis B vaccination (116,117). Vaccine antigen can be purified from the plasma of persons with chronic HBV infection or produced by recombinant DNA technology. For vaccines available in the United States, recombinant DNA technology is used to

express HBsAg in yeast, which then is purified from the cells by biochemical and biophysical separation techniques (118,119). Hepatitis B vaccines licensed in the United States are formulated to contain 10–40  $\mu\text{g}$  of HBsAg protein/mL. Hepatitis B vaccines produced for distribution in the United States do not contain thimerosal as a preservative or contain only a trace amount (<1.0  $\mu\text{g}$  mercury/mL) from the manufacturing process (120,121).

## Hepatitis B Immune Globulin

HBIG provides passively acquired anti-HBs and temporary protection (i.e., 3–6 months) when administered in standard doses. HBIG typically is used as an adjunct to hepatitis B vaccine for postexposure immunoprophylaxis to prevent HBV infection. For nonresponders to hepatitis B vaccination, HBIG administered alone is the primary means of protection after an HBV exposure.

HBIG is prepared from the plasma of donors with high concentrations of anti-HBs. The plasma is screened to eliminate donors who are positive for HBsAg, antibodies to HIV

and hepatitis C virus (HCV), and HCV RNA. In addition, proper manufacturing techniques for HBIG inactivate viruses (e.g., HBV, HCV, and HIV) from the final product (122,123). No evidence exists to indicate that HBV, HCV, or HIV ever has been transmitted by HBIG commercially available in the United States. HBIG that is commercially available in the United States does not contain thimerosal.

## Adult Vaccination Schedules and Results of Vaccination

### Preexposure Vaccination

#### Vaccination of Adults

Primary vaccination consists of  $\geq 3$  intramuscular doses of hepatitis B vaccine (Table 2). The 3-dose vaccine series administered intramuscularly at 0, 1, and 6 months produces a protective antibody response in approximately 30%–55% of healthy adults aged  $\leq 40$  years after the first dose, 75% after the second dose, and  $>90\%$  after the third dose (124,125). After age 40 years, the proportion of persons who have a protective antibody response after a 3-dose vaccination regimen declines below 90%, and by age 60 years, protective levels of antibody develop in only 75% of vaccinated persons (126). In addition to age, other host factors (e.g., smoking, obesity, genetic factors, and immune suppression) contribute to decreased vaccine response (127–130). Alternative vaccination schedules (e.g., 0, 1, and 4 months or 0, 2, and 4 months) have been demonstrated to elicit dose-specific and final rates of seroprotection similar to those obtained on a 0-, 1-, 6-month schedule (131).

The combined hepatitis A–hepatitis B vaccine (Twinrix) is indicated for vaccination of persons aged  $\geq 18$  years with risk factors for both hepatitis A and hepatitis B. The dosage of the

hepatitis A component in the combined vaccine is lower than that in the single-antigen hepatitis A vaccine, allowing it to be administered in a 3-dose schedule instead of the 2-dose schedule used for the single-antigen vaccine.

### Nonstandard Vaccine Schedules

No apparent effect on immunogenicity has been documented when minimum spacing of doses (i.e., 4 weeks between doses 1 and 2, 8 weeks between doses 2 and 3, and 16 weeks between doses 1 and 3) is not achieved precisely. Increasing the interval between the first 2 doses has little effect on immunogenicity or final antibody concentration (132–134). The third dose confers the maximum level of seroprotection but acts primarily as a booster and appears to provide optimal long-term protection (135). Longer intervals between the last 2 doses result in higher final antibody levels but might increase the risk for acquisition of HBV infection among persons who have a delayed response to vaccination. No differences in immunogenicity are observed when vaccines from different manufacturers are used to complete the vaccine series.

### Response to Revaccination

Although serologic testing for immunity is not necessary after routine vaccination of adults, postvaccination testing is recommended for persons whose subsequent clinical management depends on knowledge of their immune status, including certain health-care and public safety workers; chronic hemodialysis patients, HIV-infected persons, and other immunocompromised persons; and sex or needle-sharing partners of HBsAg-positive persons (Appendix A). Of persons who did not respond to a primary 3-dose vaccine series with anti-HBs concentrations of  $\geq 10$  mIU/mL, 25%–50% responded to an additional vaccine dose, and 44%–100% responded to a 3-dose revaccination series (136–141). Better response to

**TABLE 2. Recommended doses of currently licensed formulations of adult hepatitis B vaccine, by group and vaccine type**

| Group  | Single-antigen vaccine              |           |                                     |           | Combination vaccine                 |           |
|--|-------------------------------------|-----------|-------------------------------------|-----------|-------------------------------------|-----------|
|  | Recombivax HB <sup>®*</sup>         |           | Engerix-B <sup>®†</sup>             |           | Twinrix <sup>®†§</sup>              |           |
|  | Dose ( $\mu\text{g}$ ) <sup>¶</sup> | Vol. (mL) | Dose ( $\mu\text{g}$ ) <sup>¶</sup> | Vol. (mL) | Dose ( $\mu\text{g}$ ) <sup>¶</sup> | Vol. (mL) |
| Adults (aged $\geq 20$ years)  | 10                                  | 1.0       | 20                                  | 1.0       | 20                                  | 1.0       |
| Hemodialysis patients and other immunocompromised persons aged $\geq 20$ yrs | 40 <sup>**</sup>                    | 1.0       | 40 <sup>††</sup>                    | 2.0       | NA <sup>§§</sup>                    | NA        |

\* Merck & Co., Inc., Whitehouse Station, New Jersey.

† GlaxoSmithKline Biologicals, Rixensart, Belgium.

§ Combined hepatitis A and hepatitis B vaccine, recommended for persons aged  $\geq 18$  years who are at increased risk for both hepatitis B virus and hepatitis A virus infections.

¶ Recombinant hepatitis B surface antigen protein dose.

\*\* Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.

†† Two 1.0-mL doses administered in 1 or 2 injections on a 4-dose schedule at 0, 1, 2, and 6 months.

§§ Not applicable.

revaccination occurs in persons who have measurable but low (<10 mIU/mL) levels of antibody after the initial series (136,137). Increased vaccine doses (e.g., double the standard dose) were demonstrated to enhance revaccination response rates in one study (140) but not in another (138). Intradermal vaccination has been reported to be immunogenic in persons who did not respond to intramuscular vaccination (142,143); however, intradermal vaccination is not a route of administration indicated in the manufacturers' package labeling. Persons who do not have protective levels of anti-HBs 1–2 months after revaccination either are primary nonresponders or are infected with HBV. Genetic factors might contribute to nonresponse to hepatitis B vaccination (130,137).

### Groups Requiring Different Vaccination Doses or Schedules

Compared with immunocompetent adults, hemodialysis patients are less likely to have protective levels of antibody after vaccination with standard vaccine dosages; protective levels of antibody developed in 67%–86% (median: 64%) of adult hemodialysis patients who received 3–4 doses of either vaccine in various dosages and schedules (100). Higher seroprotection rates have been identified in patients with chronic renal failure, particularly those with mild or moderate renal failure, who were vaccinated before becoming dialysis dependent. After vaccination with a 4-dose series, the seroprotection rate among adult predialysis patients with serum creatinine levels of  $\leq 4.0$  mg/dL was 86%, compared with 37% among patients with serum creatinine levels of  $>4.0$  mg/dL, 88% of whom were dialysis patients (144).

Humoral response to hepatitis B vaccination also is reduced in other immunocompromised persons (e.g., HIV-infected persons, hematopoietic stem-cell transplant recipients, and patients undergoing chemotherapy) (145–147). Modified dosing regimens, including doubling the standard antigen dose or administering additional doses, might increase response rates (148–150). However, limited data regarding response to these alternative vaccination schedules are available.

### Immune Memory

Anti-HBs is the only easily measurable correlate of vaccine-induced protection. Immunocompetent persons who achieve anti-HBs concentrations of  $\geq 10$  mIU/mL after preexposure vaccination have nearly complete protection against both acute disease and chronic infection, even if anti-HBs concentrations decline subsequently to  $<10$  mIU/mL (151–154). Although immunogenicity is lower among immunocompromised persons, those who achieve and maintain a protective antibody

response before exposure to HBV have a high level of protection from infection (155,156).

After primary immunization with hepatitis B vaccine, anti-HBs levels decline rapidly within the first year and more slowly thereafter. Among young adults who respond to a primary vaccine series with antibody concentrations of  $\geq 10$  mIU/mL, 17%–50% have low or undetectable concentrations of anti-HBs (reflecting anti-HBs loss) 10–15 years after vaccination (155–157). In the absence of exposure to HBV, the persistence of detectable anti-HBs after vaccination depends on the concentration of postvaccination antibodies (158).

Even when anti-HBs concentrations decline to  $<10$  mIU/mL, nearly all vaccinated persons remain protected against HBV infection. The mechanism for continued vaccine-induced protection is thought to be the preservation of immune memory through selective expansion and differentiation of clones of antigen-specific B and T lymphocytes (159). Persistence of vaccine-induced immune memory among persons who responded to a primary adult vaccine series 4–23 years previously but then had anti-HBs concentrations of  $<10$  mIU/mL has been demonstrated by an anamnestic increase in anti-HBs concentrations in 74%–100% of these persons 2–4 weeks after administration of an additional vaccine dose and by antigen-specific B and T cell proliferation (160). Although direct measurement of immune memory is not yet possible, these data indicate that a high proportion of vaccinees retain immune memory and would have an anti-HBs response upon exposure to HBV.

Population-based studies of highly vaccinated populations have demonstrated elimination of new HBV infections for up to 2 decades after hepatitis B immunization programs were initiated (161–163). Breakthrough infections (detected by the presence of anti-HBc or HBV DNA) have been documented in a limited percentage of vaccinated persons (159,164), but these infections typically are transient and asymptomatic; breakthrough infections resulting in chronic HBV infection have been documented only rarely among infants born to HBsAg-positive mothers (165) and have not been observed among immunocompetent adults.

Limited data are available on the duration of immune memory after hepatitis B vaccination in immunocompromised persons (e.g., HIV-infected patients, dialysis patients, patients undergoing chemotherapy, or hematopoietic stem-cell transplant patients). No clinically significant HBV infections have been documented among immunocompromised persons who maintain protective levels of anti-HBs. In studies of long-term protection among HIV-infected persons, breakthrough infections occurring after a decline in anti-HBs concentrations to  $<10$  mIU/mL have been transient and asymptomatic (155).

However, among hemodialysis patients who responded to the vaccine, clinically significant HBV infection has been documented in persons who have not maintained anti-HBs concentrations of  $\geq 10$  mIU/mL (166).

## Postexposure Prophylaxis

Both passive-active postexposure prophylaxis (PEP) using HBIG and hepatitis B vaccine and active PEP using hepatitis B vaccine alone are highly effective in preventing infection after exposure to HBV (167–170). HBIG alone has also been demonstrated to be effective in preventing HBV transmission (68,171–173), but with the availability of hepatitis B vaccine, HBIG typically is used as an adjunct to vaccination. Guidelines for PEP for adults with occupational (174) and nonoccupational exposures (Appendix B) to HBV have been developed.

The major determinant of the effectiveness of PEP is early administration of the initial dose of vaccine. The effectiveness of PEP diminishes the longer after exposure it is initiated (27,175,176). Studies are limited on the maximum interval after exposure during which PEP is effective, but the interval is likely  $\leq 7$  days for needlestick (171,172,177) exposures and  $\leq 14$  days for sexual exposures (68,154,168,170,173).

Substantial evidence suggests that adults who respond to hepatitis B vaccination are protected from chronic HBV infection for at least 20 years even if vaccinees lack detectable anti-HBs at the time of an exposure (151–153). For this reason, immunocompetent persons who have had postvaccination testing and are known to have responded to hepatitis B vaccination with anti-HBs concentrations of  $\geq 10$  mIU/mL do not require additional passive or active immunization after an HBV exposure and do not need further periodic testing to assess anti-HBs concentrations.

## Vaccine Safety

Hepatitis B vaccines have been demonstrated to be safe when administered to infants, children, adolescents, and adults (178). Since 1982, an estimated 70 million adolescents and adults and 50 million infants and children in the United States have received  $\geq 1$  dose of hepatitis B vaccine (CDC, unpublished data, 2004).

## Vaccine Reactogenicity

The most frequently reported side effects in persons receiving hepatitis B vaccine are pain at the injection site (3%–29%) and temperature of  $>99.9^{\circ}\text{F}$  ( $>37.7^{\circ}\text{C}$ ) (1%–6%) (124,125).

However, in placebo-controlled studies, these side effects were reported no more frequently among persons receiving hepatitis B vaccine than among persons receiving placebo (179).

## Adverse Events

CDC and FDA continually assess the safety of hepatitis B vaccine and other vaccines through ongoing monitoring of data from the Vaccine Safety Datalink (VSD) project, the Vaccine Adverse Events Reporting System (VAERS), and other surveillance systems. A causal association has been established between receipt of hepatitis B vaccine and anaphylaxis (178). On the basis of VSD data, the estimated incidence of anaphylaxis among children and adolescents who received hepatitis B vaccine is one case per 1.1 million vaccine doses distributed (95% confidence interval = 0.1–3.9) (180).

Early postlicensure surveillance of adverse events suggested a possible association between Guillain-Barré syndrome (GBS) and receipt of the first dose of plasma-derived hepatitis B vaccine among U.S. adults (181). However, in a subsequent analysis of GBS cases reported to CDC, FDA, and vaccine manufacturers, among an estimated 2.5 million adults who received  $\geq 1$  dose of recombinant hepatitis B vaccine during 1986–1990, the rate of GBS that occurred after hepatitis B vaccination did not exceed the background rate among unvaccinated persons (CDC, unpublished data, 1992). An Institute of Medicine review concluded that evidence was insufficient to reject or accept a causal association between GBS and hepatitis B vaccination (178,182,183).

One retrospective case-control study (184,185) reported an association between hepatitis B vaccine and multiple sclerosis (MS) among adults. However, multiple studies (186–189) have demonstrated no such association. Reviews by scientific panels have favored rejection of a causal association between hepatitis B vaccination and MS (190,191).

In rare instances, chronic illnesses have been reported after hepatitis B vaccination, including chronic fatigue syndrome (192), neurologic disorders (e.g., leukoencephalitis, optic neuritis, and transverse myelitis) (193–195), rheumatoid arthritis (196,197), type 1 diabetes (198), and autoimmune disease (199). However, no evidence of a causal association between these conditions or other chronic illnesses and hepatitis B vaccine has been demonstrated (183,190,200–203).

Reported episodes of alopecia (hair loss) after rechallenge with hepatitis B vaccine suggest that vaccination might, in rare cases, trigger episodes of alopecia (204). However, a population-based study determined no statistically significant association between alopecia and hepatitis B vaccine (205).

## Contraindications and Precautions

Hepatitis B vaccination is contraindicated for persons with a history of hypersensitivity to yeast or any vaccine component (206–209). Despite a theoretic risk for allergic reaction to vaccination in persons with allergy to *Saccharomyces cerevisiae* (baker's yeast), no evidence exists to document adverse reactions after vaccination of persons with a history of yeast allergy.

Persons with a history of serious adverse events (e.g., anaphylaxis) after receipt of hepatitis B vaccine should not receive additional doses. As with other vaccines, vaccination of persons with moderate or severe acute illness, with or without fever, should be deferred until illness resolves (210). Vaccination is not contraindicated in persons with a history of MS, GBS, autoimmune disease (e.g., systemic lupus erythematosus or rheumatoid arthritis), or other chronic diseases.

Pregnancy is not a contraindication to vaccination. Limited data suggest that developing fetuses are not at risk for adverse events when hepatitis B vaccine is administered to pregnant women (211). Available vaccines contain noninfectious HBsAg and should cause no risk of infection to the fetus.

## Implementation Barriers and Rationale for New Recommendations

Soon after hepatitis B vaccine was licensed in 1982, ACIP recommended vaccination for adults at increased risk for HBV infection (212). However, the recommendations were not widely implemented, and coverage among adults at risk for HBV infection remained low. By the early 1990s, the difficulty in vaccinating adults at risk for HBV infection and the substantial burden of HBV-related disease resulting from infections acquired during childhood indicated that additional hepatitis B vaccination strategies were needed (213,214). In 1991, recommendations for vaccination of unvaccinated adults at high risk for HBV infection became part of the national strategy adopted by ACIP and professional medical organizations to eliminate HBV transmission in the United States (3). However, hepatitis B vaccine still is not offered routinely in medical settings serving adults, and a substantial number of adults at risk for HBV infection remain unvaccinated.

Multiple factors contribute to low hepatitis B vaccination coverage among adults at risk. In contrast to vaccination of children, no national program exists to support vaccine purchase and infrastructure for vaccine delivery to uninsured and underinsured adults. Reimbursement mechanisms for vaccination of adults with health insurance also are not widely used. In addition, certain patients and health-care providers are

reluctant to discuss risk behaviors (215), and providers might not make hepatitis B vaccination a priority compared with other clinical care services.

One strategy demonstrated to be effective at increasing vaccination coverage among adults at risk for HBV infection is to offer vaccination to all adults as part of routine prevention services in settings in which a high proportion of adults have HBV risk factors (10,216–223). In STD and HIV treatment facilities, health-care settings serving IDUs, and health-care settings targeting services to MSM, nearly all patients have behavioral risk factors for HBV infection. Furthermore, a high proportion of persons receiving health care in HIV testing facilities or correctional facilities report sexual and drug-use risk behaviors (224,225). Therefore, providing hepatitis B vaccination in these settings offers an efficient and effective way to reach adults at highest risk. During 2001–2004, in a study of 760 adults with reported acute hepatitis B who participated in CDC's Sentinel Counties Study of Viral Hepatitis, 39% reported a history of STD treatment, 40% reported a history of incarceration, and 22% reported a history of drug treatment; overall, 61% would have had at least one opportunity to be vaccinated either during STD or drug treatment or at a correctional facility (226).

Demonstration projects that supported the purchase of hepatitis B vaccine and its administration in settings in which a high proportion of adults have HBV risk factors have established the feasibility of providing the vaccine as part of comprehensive STD, HIV, and hepatitis prevention services (10). When clients were offered hepatitis B vaccination in such settings, first-dose acceptance rates of 70%–85% were achieved (10,216,223,227). These demonstration projects have identified the components of successful adult hepatitis B vaccination programs (Box 3). In addition, “one-stop” delivery of integrated prevention services was preferred by the majority of patients and typically resulted in enhanced delivery of all

### BOX 3. Components of a successful adult hepatitis B vaccination program

- Institutional commitment to the program
- Trained and knowledgeable staff who promote the program
- Patients who are informed about hepatitis B and the health benefits of hepatitis B vaccination
- Integrated delivery of vaccination and other services
- Protocols and standing orders
- Protected patient confidentiality
- Infrastructure that ensures vaccine administration is accessible, convenient, and flexible for patients
- Funding for vaccine

prevention services (227). Return visits for second and third doses of hepatitis B vaccine also provide opportunities for patients to receive other STD/HIV-related services (e.g., test results, additional counseling, and referral). Multiple studies have established the cost-effectiveness of providing hepatitis B vaccination at STD/HIV counseling and testing sites, correctional institutions, drug-abuse treatment centers, and other settings serving adults at risk for HBV infection (228–231).

Universal vaccination of adults in settings in which a high proportion of persons have HBV risk factors will reach a substantial proportion of all adults at risk for HBV infection. However, not all adults with risk factors for HBV infection visit these settings. For example, an estimated 80%–95% of STDs are diagnosed in settings other than STD clinics (232,233). Therefore, primary care and clinical preventive service providers (e.g., physicians' offices, community health centers, family planning clinics, liver disease clinics, and travel clinics) also should provide hepatitis B vaccine whenever indicated or requested as part of regular preventive care. Limited data are available regarding best practices in primary care and specialty medical settings to achieve high vaccination coverage among adults at risk for HBV infection. In one project in which hepatitis B vaccine was made available free of charge to primary care clients in community clinics, low vaccination coverage rates were observed, compared with rates at other venues (10). This finding suggests that provision of free vaccine alone might not ensure increased use of hepatitis B vaccine and that other implementation strategies (e.g., education and training of clinicians and standing orders) are needed to prompt providers to offer vaccination to adults.

In primary care settings, targeting vaccination to persons at risk is an efficient approach to preventing HBV infection. During 2001–2005, among persons with acute hepatitis B who participated in CDC's Sentinel Counties Study of Viral Hepatitis, 84% reported risk behaviors or characteristics, either during the incubation period (i.e., 6 weeks–6 months) or during their lifetimes, that placed them in a group for which hepatitis B vaccination was recommended (CDC, unpublished data, 2001–2005). Providers in primary care settings can ascertain patients' risks for HBV infection and identify candidates for hepatitis B vaccination during routine patient visits. Assessment of patients' sex- and drug-related risk factors is recommended by the U.S. Preventive Services Task Force and the American Medical Association (AMA) (234,235) and has the ancillary benefit of identifying candidates for other prevention interventions (e.g., screening for HIV infection and other STDs and drug-abuse treatment).

However, risk-targeted approaches can miss persons in need of prevention services. Patients might be reluctant to report sex-

and drug-related behaviors, particularly when these behaviors are not perceived as relevant to the clinical encounter. In addition, despite recommendations of the U.S. Preventive Services Task Force and AMA, providers might be reluctant to inquire about behavioral risk factors. For example, surveys of physicians and patients conducted during 1995–1999 indicated that fewer than half of patients were asked about sexual behaviors (236–238). Health-care providers should educate all patients about the health benefits of hepatitis B vaccination, including risk factors for HBV infection and the importance of vaccination for persons who engage in certain risk behaviors. This information might stimulate patients to request vaccination from their primary care providers, without requiring them to acknowledge a specific risk factor.

Another possible strategy is to offer vaccination to all adults in age groups with the highest incidence of infection as part of routine medical care (Figure 1). An age-based approach might simplify vaccination-related decision-making by practitioners and remove the stigma associated with disclosure of risk behaviors. Other adult vaccines, including those for influenza and pneumococcal disease, are delivered on age-based schedules. However, the effectiveness of age-based strategies in increasing hepatitis B vaccination coverage among adults at risk is unknown. In addition, age-based strategies for adult vaccination would be substantially more costly than risk-targeted approaches (CDC, unpublished data, 2005).

Lack of funding for vaccine and its administration is a major barrier to provision of hepatitis B vaccine to adults. Hepatitis B vaccine often is a reimbursable charge in health-care settings that bill insurance or Medicaid for services, and surveys of public and private insurers indicate high rates of coverage for hepatitis B vaccination (239,240). In one study, an estimated 74% of adults aged 18–49 years with risk factors for HBV infection had health insurance coverage (241). However, public clinics might not have systems in place to bill for vaccination services, and reimbursement of private providers might be inadequate to cover the purchase and administration of vaccine. Other adults either lack private insurance or are not eligible for reimbursement by Medicaid. Although the Vaccines for Children program provides federally funded vaccine and administration costs for vaccination of uninsured and underinsured children and youth aged <19 years, no similar program supports adult vaccination.

Certain adult hepatitis B vaccination programs have been successful at identifying federal, state, or local funds to provide free or low-cost hepatitis B vaccination to uninsured or underinsured adults. For example, the Immunization Grant Program, created under Section 317 of the Public Health Service Act, provides funding to state, local, and territorial

public health agencies for vaccine purchase and vaccination-program operation (242). Section 317 funds can be used to purchase childhood and adult vaccines, including adult hepatitis B vaccine. However, lack of adequate funding constrains efforts to increase vaccination coverage among adults. To maximize available resources for hepatitis B vaccination, public and private health-care providers should become familiar with insurance billing and reimbursement mechanisms that can be used for hepatitis B vaccine. AMA billing and reimbursement guidelines are available at [http://www.ama-assn.org/ama1/pub/upload/mm/36/ama\\_hep\\_coding\\_trifo.pdf](http://www.ama-assn.org/ama1/pub/upload/mm/36/ama_hep_coding_trifo.pdf).

Although HBV infections are expected to decline as a result of universal childhood immunization and increased vaccination of adults at risk, an estimated 1.25 million persons in the United States are living with chronic HBV infection and require essential prevention services and medical management. In particular, Asians/Pacific Islanders in the United States have a high prevalence of chronic HBV infection, representing a major health disparity. Persons with chronic HBV infection often are unaware of their infection status or do not receive needed care. Few programs have been implemented to identify HBsAg-positive persons, provide or refer these persons for appropriate medical management, and provide vaccination to their contacts (243). During delivery of hepatitis B vaccination and provision of other preventive services, health-care providers have opportunities to identify persons with chronic HBV infection, refer them for counseling and management, and ensure that their susceptible contacts receive vaccination. Guidelines to identify and manage HBsAg-positive persons have been developed (Appendix C).

Implementation of the recommendations and strategies outlined in this report and the companion ACIP recommendations for infants, children, and adolescents (11) should lead ultimately to the elimination of HBV transmission in the United States. New information will have implications for this effort, and adjustments and changes are expected to occur.

## Recommendations and Implementation Strategies for Hepatitis B Vaccination of Adults

### Recommendations

- Hepatitis B vaccination is recommended for all unvaccinated adults at risk for HBV infection and for all adults requesting protection from HBV infection (Box 4). Acknowledgment of a specific risk factor should not be a requirement for vaccination.

### BOX 4. Adults recommended to receive hepatitis B vaccination

#### Persons at risk for infection by sexual exposure

- Sex partners of hepatitis B surface antigen (HBsAg)-positive persons
- Sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than one sex partner during the previous 6 months)
- Persons seeking evaluation or treatment for a sexually transmitted disease
- Men who have sex with men

#### Persons at risk for infection by percutaneous or mucosal exposure to blood

- Current or recent injection-drug users
- Household contacts of HBsAg-positive persons
- Residents and staff of facilities for developmentally disabled persons
- Health-care and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids
- Persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients

#### Others

- International travelers to regions with high or intermediate levels (HBsAg prevalence of  $\geq 2\%$ ) of endemic HBV infection (Figure 4, Box 2)
- Persons with chronic liver disease
- Persons with HIV infection
- All other persons seeking protection from HBV infection

- Providers should select the vaccine schedule they consider necessary to achieve completion of the vaccine series (Table 2, Box 5).
- Public health programs and primary care providers should adopt strategies appropriate for the practice setting to ensure that all adults at risk for HBV infection are offered hepatitis B vaccine (Box 6).

### BOX 5. Hepatitis B vaccine schedules for adults (aged $\geq 20$ years)\*

0, 1, and 6 months  
0, 1, and 4 months  
0, 2, and 4 months  
0, 1, 2, and 12 months<sup>†</sup>

\* All schedules are applicable to single-antigen hepatitis B vaccines; Twinrix<sup>®</sup> (combined hepatitis A and hepatitis B vaccine) may be administered at 0, 1, and 6 months.

<sup>†</sup> A 4-dose schedule of Engerix-B<sup>®</sup> is licensed for all age groups.

**BOX 6. Implementation strategies for adult hepatitis B vaccination****Settings in which a high proportion of persons have risk factors for hepatitis B virus (HBV) infection**

- Implement standing orders to administer hepatitis B vaccine as part of routine services to all adults who have not completed vaccination.\*

**Primary care and specialty medical settings**

- Implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine services.
  - Provide information to all adults regarding the health benefits of hepatitis B vaccination, including risk factors for HBV infection and persons for whom vaccination is recommended.
  - Help adults assess their need for vaccination by obtaining a history that emphasizes risks for sexual transmission and percutaneous or mucosal exposure to blood.
  - Administer hepatitis B vaccine to all adults who report risks for HBV infection.\*
  - Provide hepatitis B vaccine to all adults seeking protection from HBV infection. Acknowledgment of a specific risk factor for HBV infection is not a requirement for vaccination.

**Occupational health programs**

- Identify staff whose work-related activities involve exposure to blood or other potentially infectious body fluids.
- Provide education to encourage vaccination.
- Implement active follow-up, with reminders to track vaccine-series completion among persons receiving vaccination.
- Provide appropriate postvaccination testing 1–2 months after vaccine-series completion.

\* In populations that have expected high rates of previous HBV infection, prevaccination testing might reduce costs by avoiding vaccination of persons who are already immune (see Appendix A, Prevaccination Serologic Testing for Susceptibility).

**BOX 7. Settings in which hepatitis B vaccination is recommended for all adults**

- Sexually transmitted disease treatment facilities
- Human immunodeficiency virus testing and treatment facilities
- Facilities providing drug-abuse treatment and prevention services
- Health-care settings targeting services to injection-drug users
- Correctional facilities
- Health-care settings targeting services to men who have sex with men
- Chronic-hemodialysis facilities and end-stage renal disease programs
- Institutions and nonresidential day care facilities for developmentally disabled persons

— when feasible, hepatitis B vaccination should be offered in outreach and other settings in which services are provided to persons at risk for HBV infection (e.g., needle-exchange programs, HIV testing sites, HIV prevention programs, and homeless shelters).

- In primary care and specialty medical settings (e.g., physician's offices, family planning clinics, community health centers, liver disease clinics, and travel clinics), providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine services. To ensure vaccination of persons at risk for HBV infection, health-care providers should
  - provide information to all adults regarding the health benefits of hepatitis B vaccination, including the risk factors for HBV infection and persons for whom vaccination is recommended;
  - help all adults assess their need for vaccination by obtaining a history that emphasizes risks for sexual transmission and percutaneous or mucosal exposure to blood;
  - administer hepatitis B vaccine to adults who report risk factors for HBV infection; and
  - provide hepatitis B vaccine to all adults requesting protection from HBV infection without requiring acknowledgment of a specific risk factor.
- Occupational health programs should
  - identify all staff whose work-related activities involve exposure to blood or other potentially infectious body fluids in a health-care, laboratory, public safety, or institutional setting (including employees, students, contractors, attending clinicians, emergency medical technicians, paramedics, and volunteers);
  - provide education to staff to encourage vaccination;

**Implementation Strategies**

- In settings in which a high proportion of persons have risk factors for HBV infection (Box 7)
  - all adults should be assumed to be at risk for HBV infection and should be offered hepatitis B vaccination if they have not completed a licensed hepatitis B vaccine series;
  - health-care providers should implement standing orders (244) to administer hepatitis B vaccine as part of routine services to adults who have not completed the vaccine series and make hepatitis B vaccination a standard component of evaluation and treatment for STDs and HIV/AIDS (Table 3); and

**TABLE 3. Recommended HIV/AIDS, sexually transmitted disease (STD), and viral hepatitis prevention services, by risk population**

| Risk population*   | Recommended services  |
|--|---|
| <b>High-risk heterosexuals</b>   |   |
| Persons seeking STD evaluation or treatment                                | Hepatitis B vaccination<br>Testing for human immunodeficiency virus (HIV) infection <sup>†</sup><br>Testing for syphilis, gonorrhea, and chlamydia, as clinically indicated <sup>§</sup>                              |
| Sexually active men not in a long-term, mutually monogamous relationship   | Hepatitis B vaccination<br>Annual testing for HIV infection <sup>†¶</sup>   |
| Sexually active women not in a long-term, mutually monogamous relationship | Hepatitis B vaccination**<br>Annual testing for HIV infection <sup>†¶</sup><br>Annual testing for chlamydia (Note: also recommended for all sexually active females aged <25 yrs) <sup>§</sup>                        |
| <b>Men who have sex with men (MSM)</b>                                     |   |
| All MSM  | Hepatitis A vaccination<br>Hepatitis B vaccination**  |
| Sexually active MSM not in a long-term, mutually monogamous relationship   | Hepatitis A vaccination<br>Hepatitis B vaccination**<br>Annual testing for HIV infection <sup>†</sup><br>Annual testing for syphilis, gonorrhea, and chlamydia <sup>§</sup>   |
| <b>Injection-drug users</b>  |   |
|  | Hepatitis A vaccination <sup>††</sup><br>Hepatitis B vaccination<br>Testing for hepatitis C virus infection <sup>§§</sup><br>Annual testing for HIV infection <sup>†</sup><br>Substance-abuse treatment <sup>¶¶</sup> |

\* Testing for HIV infection, chlamydia, gonorrhea, syphilis, and hepatitis B surface antigen also is recommended for pregnant women (CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55[No. RR-14]; CDC. Sexually transmitted diseases treatment guidelines. MMWR 2006;55[No. RR-11]; CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]).

<sup>†</sup> CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14).

<sup>§</sup> CDC. Sexually transmitted diseases treatment guidelines 2006. MMWR 2006;55(No. RR-11).

<sup>¶</sup> HIV screening is recommended for all persons aged 13–64 years. Repeat screening is recommended at least annually for persons likely to be at high risk for HIV infection, including MSM or heterosexuals who themselves or whose sex partners have had more than one partner since their most recent HIV test.

\*\* Hepatitis B vaccination is recommended for persons with more than one sex partner during the previous 6 months.

<sup>††</sup> CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-7).

<sup>§§</sup> CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19). Recommended frequency of testing for hepatitis C virus infection has not been determined.

<sup>¶¶</sup> CDC. Substance abuse treatment for injection drug users: a strategy with many benefits. Atlanta, GA: US Department of Health and Human Services, CDC; 2002. Available at <http://www.cdc.gov/idu/facts/treatment.htm>.

- implement active follow-up, with reminders to track completion of the vaccine series among persons receiving vaccination; and
- provide appropriate postvaccination testing (Appendix A).
- Providers in all settings in which hepatitis B vaccine is provided should
  - assess patients' needs for other vaccines recommended for adults (schedule available at <http://www.cdc.gov/nip/recs/adult-schedule.htm>) and administer these vaccines at the same office visit at which hepatitis B vaccine is administered;
  - identify and vaccinate all susceptible household, sex, and needle-sharing contacts of HBsAg-positive persons, and provide HBsAg-positive persons with

- appropriate referrals for counseling and medical management (Appendix C);
- provide culturally appropriate materials to educate adults about hepatitis B and the importance of vaccination (available at <http://www.cdc.gov/ncidod/diseases/hepatitis/b/index.htm#materials>);
- offer vaccination in a way that is accessible, convenient, and flexible for patients;
- be familiar with ACIP's general recommendations on immunization (210), which provide technical guidance regarding common immunization concerns of health-care providers;
- give persons who are eligible for vaccination a copy of the most current vaccine information statement for hepatitis B vaccine, as required by federal law

- (see Appendix A, Hepatitis B Vaccine Dose and Administration);
- institute methods to identify persons with a history of vaccination (see Appendix A, Unknown or Uncertain Vaccination Status);
  - provide vaccinated persons with a personal record card documenting receipt of vaccination (available at [http://www.immunize.org/guide/aov21\\_appb\\_record.pdf](http://www.immunize.org/guide/aov21_appb_record.pdf));
  - develop tracking and reminder systems to ensure completion of the vaccine series (descriptions of such systems are available at <http://www.cdc.gov/nip/publications/adultstrat.htm>);
  - report adverse events to VAERS using report forms and assistance available from CDC at telephone 1-800-822-7967 or from VAERS at <http://www.vaers.hhs.gov>; and
  - be familiar with billing and reimbursement guidelines for hepatitis B vaccination (available at [http://www.ama-assn.org/ama1/pub/upload/mm/36/ama\\_hep\\_coding\\_trifo.pdf](http://www.ama-assn.org/ama1/pub/upload/mm/36/ama_hep_coding_trifo.pdf)).
- Public health agencies and medical organizations should educate providers about the benefits of hepatitis B vaccination for their patients and methods to implement and support hepatitis B vaccination services in their settings and practices. Health departments and community-based organizations should increase awareness of the benefits of hepatitis B vaccination, particularly among persons at increased risk for HBV infection. Educational materials are available at <http://www.cdc.gov/ncidod/diseases/hepatitis/index.htm>.
  - Health departments are encouraged to implement adult immunization registries to track the receipt of hepatitis B vaccine in all settings in which adults are vaccinated. Information on immunization registries is available at <http://www.cdc.gov/nip/registry>.
  - Although hepatitis B vaccination programs aim to achieve the highest possible rate of vaccine series completion, concerns regarding completion of the hepatitis B vaccine series should not preclude initiation of hepatitis B vaccination. Each dose of vaccine confers some protection against HBV infection. Vaccine immunogenicity is not decreased by lengthened intradose intervals, and the second and third doses can be administered during subsequent health-care visits outside of the recommended vaccine schedule.

### Acknowledgments

The following persons contributed to the development of this report: Guthrie S. Birkhead, MD, AIDS Institute, New York State Department of Health, Albany, New York; Anna S. F. Lok, MD, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan; Molli C. Conti, Hepatitis B Foundation, Doylestown, Pennsylvania; Josiah D. Rich, MD, Brown University, Providence, Rhode Island; Robert A. Gunn, MD, San Diego County Health and Human Services Agency, San Diego, California; Harold S. Margolis, MD, Joanna Buffington, MD, Alison Greenspan, MPH, Stephanie M. Neitzel, Kevin P. O'Connor, MA, Annemarie Wasley, PhD, Brigette F. Ulin, MPH, Ian T. Williams, PhD, Division of Viral Hepatitis, Matthew T. McKenna, MD, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed); William L. Atkinson, MD, Edward W. Brink, MD, Immunization Services Division, Susan A. Maloney, MD, Division of Global Migration and Quarantine, National Center for Immunization and Respiratory Diseases (proposed), CDC.

### References

1. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. *MMWR* 1982;31:317–22, 327–8.
2. CDC. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. *MMWR* 1988;37:341–6, 351.
3. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). *MMWR* 1991;40(No. RR-13).
4. CDC. Update: recommendations to prevent hepatitis B virus transmission—United States. *MMWR* 1995;44:574–5.
5. CDC. Update: recommendations to prevent hepatitis B virus transmission—United States. *MMWR* 1999;48:33–4.
6. CDC. Prevention of perinatal hepatitis B through enhanced case management—Connecticut, 1994–95, and the United States, 1994. *MMWR* 1996;45:584–7.
7. CDC. National, state, and urban area vaccination coverage among children aged 19–35 months—United States, 2005. *MMWR* 2006;55:988–93.
8. Stokley S, McCauley M, Fishbein D, Stephenson J. Adolescent vaccination coverage levels: results from the 1997–2003 National Health Interview Survey [Presentation]. Presented at the 40th National Immunization Conference, Atlanta, GA; March 6, 2006.
9. CDC. Hepatitis B vaccination coverage among adults—United States, 2004. *MMWR* 2006;55:509–11.
10. CDC. Hepatitis B vaccination among high-risk adolescents and adults—San Diego, California, 1998–2001. *MMWR* 2002;51:618–21.
11. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. *MMWR* 2005;54(No. RR-16).
12. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. *N Engl J Med* 1979;300:101–6.

13. Hoofnagle JH, DiBisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. *Semin Liver Dis* 1991;11:73–83.
14. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985; 151:599–603.
15. Dienstag JL. Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection. *Springer Semin Immunopathol* 1981;3:461–72.
16. CDC. Hepatitis surveillance: report number 60. Atlanta, GA: US Department of Health and Human Services, CDC; 2005.
17. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. *Proc Biol Sci* 1993;253:197–201.
18. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. *Lancet* 1983;2(8359):1099–102.
19. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. *Clin Infect Dis* 1995;20:992–1000.
20. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. *J Infect Dis* 1991;163:454–9.
21. Polish LB, Shapiro CN, Bauer F, et al. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded fingerstick device. *N Engl J Med* 1992;326:721–5.
22. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate hepatitis B disease burden and vaccination impact. *Int J Epidemiol* 2005;34:1329–39.
23. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Disease (AASLD). Chronic hepatitis B. *Hepatology* 2001;34:1225–41.
24. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Disease (AASLD). Chronic hepatitis B: update of recommendations. *Hepatology* 2004;39:857–61.
25. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Disease (AASLD). Management of hepatocellular carcinoma. *Hepatology* 2005;42:1208–36.
26. American Association for the Study of Liver Diseases. Practice guidelines. Alexandria, VA: American Association for the Study of Liver Diseases; 2006. Available at <http://www.aasld.org>.
27. Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Griffin DE, et al., eds. *Fields virology*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
28. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. *Transfusion* 2003;43:788–98.
29. Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B. Hepatitis B surface antigenemia in blood donors following vaccination. *Transfusion* 1995;35:475–7.
30. Lunn ER, Hoggarth BJ, Cook WJ. Prolonged hepatitis B surface antigenemia after vaccination. *Pediatrics* 2000;105:E81.
31. Kao JH, Chen PJ, Lai MY, Chen DS. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. *Hepatology* 2001;34(4 Pt 1):817–23.
32. Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. *J Infect Dis* 1985;151:604–9.
33. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. *Hepatology* 1991; 13:627–31.
34. Adachi H, Kaneko S, Matsushita E, Inagaki Y, Unoura M, Kobayashi K. Clearance of HBsAg in seven patients with chronic hepatitis B. *Hepatology* 1992;16:1334–7.
35. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. *Ann Intern Med* 2001;135:759–68.
36. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, DiBisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. *Clin Infect Dis* 1998;26:895–7.
37. Grob P, Jilg W, Bornhak H, et al. Serological pattern “anti-HBc alone”: report on a workshop. *J Med Virol* 2000;62:450–5.
38. De Feo TM, Poli F, Mozzi F, Moretti MP, Scalapogna M, Collaborative Kidney, Liver and Heart North Italy Transplant Program Study Groups. Risk for transmission of hepatitis B virus from anti-HBc positive cadaveric organ donors: a collaborative study. *Transplantation Proc* 2005;37:1238–9.
39. Lai CL, Lau JY, Yeoh EK, Chang WK, Lin HJ. Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. *J Med Virol* 1992;36:180–3.
40. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. *Gastroenterology* 1992;103:590–4.
41. Alter HJ, Seeff LB, Kaplan PM, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. *N Engl J Med* 1976;295:909–13.
42. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. *J Infect Dis* 1977;136:571–6.
43. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. *Hepatology* 2006;43(2 Suppl 1):S173–81.
44. Brunetto MR, Stemler M, Schodel F, et al. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. *Ital J Gastroenterol* 1989;21:151–4.
45. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. *Lancet* 1989;2(8663):588–91.
46. Bancroft WH, Snitbhan R, Scott RM, et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. *J Infect Dis* 1977;135:79–85.
47. Alter HJ, Purcell RH, Gerin JL, et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. *Infect Immun* 1977;16:928–33.
48. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. *Lancet* 1981;1(8219):550–1.
49. Favero MS, Bond WW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. *J Infect Dis* 1974;129:210–2.
50. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. *Transfusion* 2003;43:788–98.
51. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk for transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. *N Engl J Med* 1996;334:1685–90.

52. CDC. Blood safety monitoring among persons with bleeding disorders—United States, May 1998–June 2002. *MMWR* 2003;51:1152–4.
53. Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. *Ann Intern Med* 1983;99:330–3.
54. Canter J, Mackey K, Good LS, et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. *Arch Intern Med* 1990;150:1923–7.
55. Hlady WG, Hopkins RS, Ogilby TE, Allen ST. Patient-to-patient transmission of hepatitis B in a dermatology practice. *Am J Public Health* 1993;83:1689–93.
56. Kent GP, Brondum J, Keenlyside RA, LaFazia LM, Scott HD. A large outbreak of acupuncture-associated hepatitis B. *Am J Epidemiol* 1988;127:591–8.
57. Limentani AE, Elliott LM, Noah ND, Lamborn JK. An outbreak of hepatitis B from tattooing. *Lancet* 1979;2(8133):86–8.
58. Cancio-Bello TP, de Medina M, Shorey J, Valledor MD, Schiff ER. An institutional outbreak of hepatitis B related to a human biting carrier. *J Infect Dis* 1982;146:652–6.
59. MacQuarrie MB, Forghani B, Wolochow DA. Hepatitis B transmitted by a human bite. *JAMA* 1974;230:723–4.
60. Scott RM, Snitbhan R, Bancroft WH, Alter HJ, Tingpalapong M. Experimental transmission of hepatitis B virus by semen and saliva. *J Infect Dis* 1980;142:67–71.
61. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. *J Infect Dis* 2002;185:713–9.
62. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. *Med Clin North Am* 1990;74:1529–41.
63. Thomas DL, Cannon RO, Shapiro CN, Hook EW 3rd, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. *J Infect Dis* 1994;169:990–5.
64. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. *Sex Transm Dis* 2001;28:166–70.
65. MacKellar DA, Valleroy LA, Secura GM, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. *Am J Public Health* 2001;91:965–71.
66. Koff RS, Slavin MM, Connelly JD, Rosen DR. Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. *Gastroenterology* 1977;72:297–300.
67. Peters CJ, Purcell RH, Lander JJ, Johnson KM. Radioimmunoassay for antibody to hepatitis B surface antigen shows transmission of hepatitis B virus among household contacts. *J Infect Dis* 1976;134:218–23.
68. Redeker AG, Mosley JW, Gocke DJ, McKee AP, Pollack W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. *N Engl J Med* 1975;293:1055–9.
69. Bernier RH, Sampliner R, Gerety R, Tabor E, Hamilton F, Nathanson N. Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. *Am J Epidemiol* 1982;116:199–211.
70. Heathcote J, Gateau P, Sherlock S. Role of hepatitis-B antigen carriers in non-parenteral transmission of the hepatitis-B virus. *Lancet* 1974;2(7877):370–1.
71. Irwin GR, Allen AM, Bancroft WH, Karwacki JJ, Pinkerton RH, Russell PK. Hepatitis B antigen and antibody. Occurrence in families of asymptomatic HBsAg carriers. *JAMA* 1974;227:1042–3.
72. Levine OS, Vlahov D, Brookmeyer R, Cohn S, Nelson KE. Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. *J Infect Dis* 1996;173:579–83.
73. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk for infection with hepatitis B and C viruses. *Am J Epidemiol* 1999;149:203–13.
74. DesJarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. *Am J Epidemiol* 2003;157:467–71.
75. Bialek SR, Bower WA, Mottram K, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. *J Urban Health* 2005;82:468–78.
76. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. *Am J Public Health* 2002;92:385–7.
77. Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. *Addiction* 2001;96:589–95.
78. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. *Epidemiol Infect* 2001;127:475–84.
79. Tien PC, Kovacs A, Bacchetti P, et al. Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. *Clin Infect Dis* 2004;39:1363–70.
80. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. *J Infect Dis* 2003;188:571–7.
81. Steinberg SC, Alter HJ, Leventhal BG. The risk for hepatitis transmission to family contacts of leukemia patients. *J Pediatr* 1975;87:753–6.
82. Nordenfelt E, Dahlquist E. HBsAg positive adopted children as a cause of intrafamilial spread of hepatitis B. *Scand J Infect Dis* 1978;10:161–3.
83. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. *Pediatrics* 1992;89:269–73.
84. Franks AL, Berg CJ, Kane MA, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. *N Engl J Med* 1989;321:1301–5.
85. Mahoney FJ, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana. *Pediatrics* 1995;96:1113–6.
86. Perrillo RP, Strang S, Lowry OH. Different operating conditions affect risk for hepatitis B virus infection at two residential institutions for the mentally disabled. *Am J Epidemiol* 1986;123:690–8.
87. Perrillo RP, Storch GA, Bodicky CJ, Campbell CR, Sanders GE. Survey of hepatitis B viral markers at a public day school and a residential institution sharing mentally handicapped students. *J Infect Dis* 1984;149:796–800.

88. Chaudhary RK, Perry E, Cleary TE. Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. *Am J Epidemiol* 1977;105:123–6.
89. Woodruff BA, Vazquez E. Prevalence of hepatitis virus infections in an institution for persons with developmental disabilities. *Am J Ment Retard* 2002;107:278–92.
90. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? *Am J Epidemiol* 1982;115:26–39.
91. Hadler SC, Doto IL, Maynard JE, et al. Occupational risk for hepatitis B infection in hospital workers. *Infect Control* 1985;6:24–31.
92. US Department of Labor, Occupational Safety and Health Administration, 29 CFR Part 1910.1030. Occupational exposure to bloodborne pathogens: final rule. *Federal Register* 1991;56:640004–182.
93. CDC. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. *MMWR* 1989;38(Suppl 6).
94. Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. *Arch Intern Med* 1997;157:2601–5.
95. Spitters C, Zenilman J, Yeagain J, Pardoe K. Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program. *J Occup Environ Med* 1995;37:663–4.
96. Werman HA, Gwinn R. Seroprevalence of hepatitis B and hepatitis C among rural emergency medical care personnel. *Am J Emerg Med* 1997;15:248–51.
97. Woodruff BA, Moyer LA, O'Rourke KM, Margolis HS. Blood exposure and the risk for hepatitis B virus infection in firefighters. *J Occup Med* 1993;35:1048–54.
98. Averhoff FM, Moyer LA, Woodruff BA, et al. Occupational exposures and risk for hepatitis B virus infection among public safety workers. *J Occup Environ Med* 2002;44:591–6.
99. Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. *J Infect Dis* 1986;153:1149–51.
100. CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR* 2001;50(No. RR-5).
101. CDC. Outbreaks of hepatitis B virus infection among hemodialysis patients—California, Nebraska, and Texas, 1994. *MMWR* 1996;45:285–9.
102. Bell BP. Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. *Acta Gastroenterol Belg* 2000;63:359–63.
103. Steffen R. Risks of hepatitis B for travellers. *Vaccine* 1990; (8 Suppl):S31–2.
104. Lange WR, Frame JD. High incidence of viral hepatitis among American missionaries in Africa. *Am J Trop Med Hyg* 1990;43:527–33.
105. Ohara H, Ebisawa I, Naruto H. Prophylaxis of acute viral hepatitis by immune serum globulin, hepatitis B vaccine, and health education: a sixteen year study of Japan overseas cooperation volunteers. *Am J Trop Med Hyg* 1997;56:76–9.
106. Holland CA, Ma Y, Moscicki B, Durako SJ, Levin L, Wilson CM. Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network. *Sex Transm Dis* 2000; 27:296–303.
107. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol* 2006;44(1 Suppl):S6–9.
108. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. *Clin Infect Dis* 1994;18:339–47.
109. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. *Eur J Clin Microbiol Infect Dis* 2000;19:237–9.
110. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk for liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002;360(9349):1921–6.
111. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. *Am J Public Health* 1999;89:14–8.
112. Barnes JS, Bennett CE. The Asian population: 2000. Census 2000 brief. Washington, DC: US Department of Commerce, US Census Bureau; 2002.
113. Chao S, Le PV, Prapong W, Su J, So S. High prevalence of chronic hepatitis B (HBV) infection in adult Chinese Americans living in California [Abstract]. *Hepatology* 2004;40(4 Suppl 1):717A.
114. Guane R, Siu P, Lam K, et al. Prevalence of HBV and risk for HBV acquisition in hepatitis B screening programs in large metropolitan cities in the United States [Abstract]. *Hepatology* 2004; 40(4 Suppl 1):716A.
115. US Department of Homeland Security, Office of Immigration Statistics. 2003 yearbook of immigration statistics. Washington, DC: US Department of Homeland Security; 2004.
116. Purcell RH, Gerin JL. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. *Am J Med Sci* 1975;270:395–9.
117. Hilleman MR, McAleer WJ, Buynak EB, McLean AA. Quality and safety of human hepatitis B vaccine. *Dev Biol Stand* 1983;54:3–12.
118. Emini EA, Ellis RW, Miller WJ, McAleer WJ, Scolnick EM, Gerety RJ. Production and immunological analysis of recombinant hepatitis B vaccine. *J Infect* 1986;13(Suppl A):3–9.
119. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. *Vaccine* 1990;8(Suppl):S69–73.
120. CDC. Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. *MMWR* 1999;48:780–2.
121. CDC. Update: expanded availability of thimerosal preservative-free hepatitis B vaccine. *MMWR* 2000;49:642, 651.
122. CDC. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. *MMWR* 1986; 35:231–3.
123. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. *Transfusion* 1986;26:210–13.
124. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. *Am J Med* 1989;87(Suppl 3A):S14–20.
125. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. *J Infect* 1986;13(Suppl A):39–45.
126. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk for hepatitis B virus infection. *Am J Prev Med* 1998;15:1–8.

127. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. *Vaccine* 1989;7:425–30.
128. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. *JAMA* 1985;254:3187–9.
129. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. *JAMA* 1993;270:2935–9.
130. Alper CA, Kruskal MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. *N Engl J Med* 1989;321:708–12.
131. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. *N Engl J Med* 1997;336:196–204.
132. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. *Vaccine* 1989;7:106–10.
133. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. *Pediatrics* 1999;103(6 Pt 1):1243–7.
134. Wistrom J, Ahlm C, Lundberg S, Settergren B, Tarnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. *Vaccine* 1999;17:2162–5.
135. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. *J Infect Dis* 1989;160:766–9.
136. Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance. *Vaccine* 1997;15:349–52.
137. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. *Ann Intern Med* 1986;105:356–60.
138. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. *Vaccine* 1997;15:353–6.
139. Kim MJ, Nafziger AN, Harro CD, et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. *Vaccine* 2003;21:1174–9.
140. Bertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. *J Infect Dis* 1997;175:678–81.
141. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. *JAMA* 1988;260:1734–8.
142. Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. *Infect Control Hosp Epidemiol* 1995;16:88–91.
143. Nagafuchi S, Kashiwagi S, Okada K, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. *JAMA* 1991;265:2679–83.
144. Fraser GM, Ochana N, Fenyves D, et al. Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. *J Hepatol* 1994;21:450–4.
145. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. *Ann Intern Med* 1988;109:101–5.
146. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. *J Clin Gastroenterol* 1992;14:27–30.
147. Loke RH, Murray-Lyon IM, Coleman JC, Evans BA, Zuckerman AJ. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. *J Med Virol* 1990;31:109–11.
148. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. *Vaccine* 2000;18:1161–5.
149. Choudhury SA, Peters VB. Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 1995;14:65–7.
150. Fonseca MO, Pang LW, de Paula Cavaleiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. *Vaccine* 2005;23:2902–8.
151. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multicenter efficacy trial among homosexual men. *Ann Intern Med* 1982;97:362–6.
152. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med* 1986;315:209–14.
153. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? *J Infect Dis* 1999;179:489–92.
154. Szmunes W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. *N Engl J Med* 1980;303:833–41.
155. Hadler SC, Coleman PJ, O'Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Hollinger FB, Lemon SM, Margolis H, eds. *Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease*. Baltimore, MD: Williams & Wilkins; 1991:776–8.
156. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. *Pediatrics* 1992;90(1 Pt 2):170–3.
157. Dentinger CM, McMahon BJ, Fiore AE. Anti-HBs persistence and response to a hepatitis B (HG) vaccine boost among Yup'ik Eskimos 23 years after HB vaccination [Poster 1028]. Annual Meeting of the Infectious Disease Society of America, San Francisco, California; October 6–9, 2005.
158. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. *Pediatr Infect Dis J* 2003;22:157–63.
159. Banatvala JE, Van Damme P. Hepatitis B vaccine—do we need boosters? *J Viral Hepat* 2003;10:1–6.
160. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. *Vaccine* 2006;30:572–7.

161. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. *J Infect Dis* 2000;181:413–8.
162. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. *J Infect Dis* 2003;187:134–8.
163. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. *Lancet* 2005;366(9494):1379–84.
164. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, eds. *Vaccines*. 4th ed. Orlando, FL: WB Saunders Co.; 2003:299–337.
165. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. *J Infect Dis* 1999;179:1319–25.
166. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmunes W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. *N Engl J Med* 1984;311:496–501.
167. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. *J Med Virol* 1994;44:144–51.
168. Papaevangelou G, Roumeliotou-Karayannis A, Richardson SC, Nikolakakis P, Kalafatas P. Postexposure immunoprophylaxis of spouses of patients with acute viral hepatitis B. In: Zuckerman AJ, ed. *Viral hepatitis and liver disease*. New York, NY: Alan R. Liss, Inc.; 1988:992–4.
169. Mitsui T, Iwano K, Suzuki S, et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. *Hepatology* 1989;10:324–7.
170. Roumeliotou-Karayannis A, Dandolo E, Richardson SC, Papaevangelou G. Immunogenicity of a reduced dose of recombinant hepatitis B vaccine. *Vaccine* 1986;4:93–4.
171. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. *Ann Intern Med* 1978;88:285–93.
172. Grady GE, Lee VA, Prince AM, et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. *J Infect Dis* 1978;138:625–38.
173. Perrillo RP, Campbell CR, Strang S, Bodicky CJ, Costigan DJ. Immune globulin and hepatitis B immune globulin. Prophylactic measures for intimate contacts exposed to acute type B hepatitis. *Arch Intern Med* 1984;144:81–5.
174. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. *MMWR* 2001;50(No. RR-11).
175. Grady GE. Viral hepatitis: passive prophylaxis with globulins—state of the art in 1978. In: Vyas GN, Cohen SN, Schmid R, eds. *Viral hepatitis: a contemporary assessment of etiology, epidemiology, pathogenesis, and prevention*. Philadelphia, PA: Franklin Institute Press; 1978:467–76.
176. Beasley RP, Stevens CE. Vertical transmission of HBV and interruption with globulin. In: Vyas GN, Cohen SN, Schmid R, eds. *Viral hepatitis: a contemporary assessment of etiology, epidemiology, pathogenesis, and prevention*. Philadelphia, PA: Franklin Institute Press; 1978:333–45.
177. Mitsui T, Iwano K, Suzuki S, et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. *Hepatology* 1989;10:324–7.
178. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. *JAMA* 1994;271:1602–5.
179. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. *Pediatr Infect Dis J* 1993;12:438–45.
180. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. *Pediatrics* 2003;112:815–20.
181. Shaw FE Jr, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. *Am J Epidemiol* 1988;127:337–52.
182. CDC. Update: vaccine side effects, adverse reactions, contraindications, and precautions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1996;45(No. RR-12).
183. Stratton KR, Howe CJ, Johnston RB Jr, eds. *Adverse events associated with childhood vaccines: evidence bearing on causality*. Washington, DC: Institute of Medicine, National Academies Press; 1994.
184. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. *Neurology* 2004;63:838–42.
185. MacIntyre CR, Kelly H, Jolley D, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study [Letter]. *Neurology* 2005;64:1317.
186. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med* 2001;344:327–32.
187. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. *Vaccines in Multiple Sclerosis Study Group*. *N Engl J Med* 2001;344:319–26.
188. DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. *Expert Rev Vaccines* 2002;1:461–6.
189. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch Neurol* 2003;60:504–9.
190. Stratton K, Almario D, McCormick MC, eds. *Immunization safety review: hepatitis B vaccine and central nervous system demyelinating disorders*. Washington, DC: Institute of Medicine, National Academies Press; 2002.
191. Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and demyelinating neurological diseases. *Pediatr Infect Dis J* 1999;18:23–4.
192. Anonymous. Alleged link between hepatitis B vaccine and chronic fatigue syndrome. *Can Dis Wkly Rep* 1991;17:215–6.
193. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. *Lancet* 1991;338(8776):1174–5.
194. Trevisani F, Gattinara GC, Caraceni P, et al. Transverse myelitis following hepatitis B vaccination. *J Hepatol* 1993;19:317–8.
195. Konstantinou D, Paschalis C, Maraziotis T, Dimopoulos P, Bassaris H, Skoutelis A. Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient. *Clin Infect Dis* 2001;33:1772–3.

196. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. *J Rheumatol* 1998;25:1687-93.
197. Maillefert JF, Sibilia J, Toussiroit E, et al. Rheumatic disorders developed after hepatitis B vaccination. *Rheumatology (Oxford)* 1999;38:978-83.
198. Classen JB. Childhood immunisation and diabetes mellitus. *N Z Med J* 1996;109(1022):195.
199. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B. *Nephron* 1992;62:236.
200. Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. *Pediatr Infect Dis J* 1999;18:23-4.
201. Institute for Vaccine Safety Diabetes Workshop Panel. Childhood immunization and type I diabetes: summary of an Institute for Vaccine Safety workshop. *Pediatr Infect Dis J* 1999;18:217-22.
202. DeStefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and risk for type 1 diabetes mellitus. *Pediatrics* 2001;108:E112.
203. DeStefano F, Gu D, Kramarz P, et al. Childhood vaccinations and risk of asthma. *Pediatr Infect Dis J* 2002;21:498-504.
204. Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. *JAMA* 1997;278:1176-8.
205. Schwalbe JA, Ray P, Black SB, et al. Risk for alopecia after hepatitis B vaccination [Abstract]. Presented at the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California; September 24-27, 1998.
206. Merck & Co., Inc. Recombivax HB®: hepatitis B vaccine (recombinant) [Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 1998.
207. GlaxoSmithKline Biologicals. Engerix-B® [Package insert]. Rixensart, Belgium: GlaxoSmithKline Biologicals; 1998.
208. GlaxoSmithKline Biologicals. Pediarix® [Package insert]. Rixensart, Belgium: GlaxoSmithKline Biologicals; 2003.
209. Merck & Co., Inc. Comvax® [Package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2004.
210. CDC. General recommendations on immunization, 2006: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. In press.
211. Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. *Am J Perinatol* 1991;8:227-32.
212. CDC. Inactivated hepatitis B virus vaccine. *MMWR* 1982;31:317-22, 327-8.
213. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. *JAMA* 1990;263:1218-22.
214. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. *Pediatrics* 2001;108:1123-8.
215. Liddicoat RV, Horton NJ, Urban R, Maier E, Christiansen D, Samet JH. Assessing missed opportunities for HIV testing in medical settings. *J Gen Intern Med* 2004;19:349-56.
216. Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. *J Urban Health* 2005;82:151-61.
217. Charuvastra A, Stein J, Schwartzapfel B, et al. Hepatitis B vaccination practices in state and federal prisons. *Public Health Rep* 2001;116:203-9.
218. Gilbert LK, Bulger J, Scanlon K, Ford K, Bergmire-Sweat D, Weinbaum C. Integrating hepatitis B prevention into sexually transmitted disease services. *Sex Transm Dis* 2005;32:346-50.
219. Savage RB, Hussey MJ, Hurie MB. A successful approach to immunizing men who have sex with men against hepatitis B. *Public Health Nurs* 2000;17:202-6.
220. Samoff E, Dunn A, VanDevanter N, Blank S, Weisfuse IB. Predictors of acceptance of hepatitis B vaccination in an urban sexually transmitted diseases clinic. *Sex Transm Dis* 2004;31:415-20.
221. Sansom S, Rudy E, Strine T, Douglas W. Hepatitis A and B vaccination in a sexually transmitted disease clinic for men who have sex with men. *Sex Transm Dis* 2003;30:685-8.
222. CDC. Hepatitis B vaccination for injection drug users—Pierce County, Washington, 2000. *MMWR* 2001;50:388-90, 399.
223. CDC. Hepatitis B vaccination of inmates in correctional facilities—Texas, 2000-2002. *MMWR* 2004;53:681-3.
224. CDC. Prevention and control of infections with hepatitis viruses in correctional settings. *MMWR* 2003;52(No. RR-1).
225. CDC. HIV counseling and testing in publicly funded sites. Atlanta, GA: US Department of Health and Human Services, CDC; 2001.
226. Williams IT, Boaz K, Openo K, et al. Missed opportunities for hepatitis B vaccination in correctional settings, sexually transmitted disease (STD) clinics, and drug treatment programs [Abstract]. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, California; October 6-9, 2005.
227. Gunn RA, Lee MA, Callahan DB, Gonzales P, Murray PJ, Margolis HS. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. *Am J Prev Med* 2005;29:27-33.
228. Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. *Am J Prev Med* 2006;30:498-506.
229. Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. *Vaccine* 2002;21:312-21.
230. Rich JD, Ching CG, Lally MA, et al. A review of the case for hepatitis B vaccination of high-risk adults. *Am J Med* 2003;114:316-8.
231. Billah K, Buffington J, Weinbaum C, et al. Economic implications of hepatitis B vaccination of adults at sexually transmitted disease clinics in the United States [Poster]. Presented at the 2004 National STD Prevention Conference, Philadelphia, Pennsylvania; March 8-11, 2004.
232. St Lawrence JS, Montano DE, Kasprzyk D, Phillips WR, Armstrong K, Leichter JS. STD screening, testing, case reporting, and clinical and partner notification practices: a national survey of US physicians. *Am J Public Health* 2002;92:1784-8.
233. CDC. Sexually transmitted disease surveillance, 2004. Table A2: reported cases of sexually transmitted disease by sex and reporting source: United States, 2004. Atlanta, GA: US Department of Health and Human Services, CDC; 2005. Available at <http://www.cdc.gov/std/stats/tables/tablea2.htm>.
234. US Preventive Services Task Force. Counseling to prevent HIV infection and other sexually transmitted diseases. Guide to clinical preventive services. 2nd ed. Washington, DC: US Department of Health and Human Services; 1996.
235. American Medical Association. Immunizing high-risk populations. Chicago, IL: American Medical Association; 2004.
236. Maheux B, Haley N, Rivard M, Gervais A. STD risk assessment and risk-reduction counseling by recently trained family physicians. *Acad Med* 1995;70:726-8.

237. Bull SS, Rietmeijer C, Fortenberry JD, et al. Practice patterns for the elicitation of sexual history, education, and counseling among providers of STD services: results from the gonorrhea community action project (GCAP). *Sex Transm Dis* 1999;26:584–9.
238. Maheux B, Haley N, Rivard M, Gervais A. Do physicians assess lifestyle health risks during general medical examinations? A survey of general practitioners and obstetrician-gynecologists in Quebec. *CMAJ* 1999;160:1830–4.
239. Davis MM, Thrall JS, Gebremariam A, et al. Benefits coverage for adult vaccines in employer-sponsored health plans [Presentation]. Presented at the 38th National Immunization Conference, Nashville, Tennessee; May 12, 2006. Available at [http://cdc.confex.com/cdc/nic2004/techprogram/paper\\_4906.htm](http://cdc.confex.com/cdc/nic2004/techprogram/paper_4906.htm).
240. Rosenbaum S, Stewart A, Cox M, Lee A. The epidemiology of U.S. immunization law: a national study for the National Immunizations Program, Centers for Disease Control and Prevention. Medicaid coverage of immunizations for non-institutionalized adults. Washington, DC: George Washington University Medical Center, School of Public Health and Health Services, Center for Health Services Research and Policy; 2003. Available at [http://www.gwumc.edu/sphhs/healthpolicy/chsrp/downloads/Medicaid\\_Immunization\\_Study.pdf](http://www.gwumc.edu/sphhs/healthpolicy/chsrp/downloads/Medicaid_Immunization_Study.pdf).
241. Jain N, Yusuf H, Wortley PM, Euler GL, Walton S, Stokley S. Factors associated with receiving hepatitis B vaccination among high-risk adults in the United States: an analysis of the National Health Interview Survey, 2000. *Fam Med* 2004;36:480–6.
242. CDC. Programs in brief: immunizations. Immunization Grant Program (Section 317). Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at <http://www.cdc.gov/programs/immun03.htm>.
243. Weinberg MS, Gunn RA, Mast EE, Gresham L, Ginsberg M. Preventing transmission of hepatitis B virus from people with chronic infection. *Am J Prev Med* 2001;20:272–6.
244. CDC. Use of standing orders programs to increase adult vaccination rates: recommendations of the Advisory Committee on Immunization Practices. *MMWR* 2000;49(No. RR-1):15–26.

## Appendix A

### Immunization Management Issues

#### Hepatitis B Vaccine Dose and Administration

- Recommended vaccine doses vary by product, age of recipient, and needs of special populations (see Table 2). Although the antigen contents of vaccines differ, vaccines made by different manufacturers are interchangeable for all adult schedules.
- Hepatitis B vaccine should be administered by intramuscular injection. The deltoid muscle is the recommended site of administration for adults. Injection into the buttock is associated with decreased immunogenicity (1–4). Intradermal administration can result in a lower seroconversion rate and final concentration of antibody to hepatitis B surface antigen (anti-HBsAg) compared with intramuscular administration; limited data are available to assess long-term protection from this route of administration (5,6).
- For intramuscular injection, the needle should be long enough to reach the muscle mass and prevent vaccine from seeping into subcutaneous tissue, but not so long as to involve underlying nerves and blood vessels or bone (7). The appropriate needle length for adults is 1”–1½” (25–38 mm), depending on the recipient’s weight (1” [25 mm] for males and females weighing <60 kg [<130 lbs]; 1”–1½” [25–38 mm] for females weighing 60–90 kg [130–200 lbs] and males weighing 60–118 kg [130–260 lbs]; and 1½” [38 mm] for females weighing >90 kg [>200 lbs] and males weighing >118 kg [>260 lbs]). A 22- to 25-gauge needle should be used.\*
- Hepatitis B vaccine administered by any route or site other than intramuscularly in the deltoid muscle should not be counted as valid and should be repeated unless serologic testing indicates that an adequate response has been achieved (see Postvaccination Testing for Serologic Response).
- Hepatitis B vaccine and other vaccines administered during the same visit should be given in different injection sites.
- For persons at risk for hemorrhage (e.g., persons with hemophilia), the risk for bleeding after intramuscular injection can be minimized by using a 23-gauge (or smaller) needle, applying direct pressure to the injection site for 1–2 minutes, and administering vaccine immedi-

ately after infusion of coagulation factor. Subcutaneous administration of vaccine can be considered for these persons but might result in lower response and increased local reaction.

- Hepatitis B vaccine should be stored at 35°F–46°F (2°C–8°C) and should not be frozen.
- A vaccine information statement (VIS) must be provided to recipients of hepatitis B vaccine. The National Childhood Vaccine Injury Act of 1986 (42 U.S.C. § 300aa-26) requires vaccine providers to give a copy of the most current vaccine-specific VIS to all recipients of vaccines that are included on the National Vaccine Injury Compensation Program table maintained by the Health Resources and Services Administration (available at <http://www.hrsa.gov>). Hepatitis B vaccine is included on this table. The most current VIS for hepatitis B vaccine is available at <http://www.cdc.gov/nip/publications/vis>. Statements in languages other than English are available from the Immunization Action Coalition at <http://www.immunize.org>.
- Adverse events should be reported to the Vaccine Adverse Events Reporting System; report forms and assistance are available from CDC at telephone 1-800-822-7967 or at <http://www.vaers.hhs.gov>.

#### Hepatitis B Immune Globulin (HBIG) Dose and Administration

- The standard dose of HBIG is 0.06 mL/kg for all applications in adults.
- HBIG may be administered simultaneously with hepatitis B vaccine but in a different injection site.
- HBIG is administered by intramuscular injection. An appropriate muscle mass (i.e., deltoid or gluteal) should be chosen in which to deliver the large volumes of HBIG required by using a needle length appropriate for the person’s age and size (7).
- HBIG should be stored at 35°F–46°F (2°C–8°C) and should not be frozen.

#### Unknown or Uncertain Vaccination Status

- A reliable vaccination history is defined as a written, dated record (e.g., personal, school, physician, or immunization registry) of each dose of a complete series.

\* Certain experts recommend a 5/8” (16 mm) needle for males and females weighing <60 kg (<130 lbs) (7).

- In the majority of clinical practice settings, providers should accept only written and dated records as evidence of vaccination. Although vaccinations should not be postponed if records cannot be located, providers should try to locate missing records by contacting previous health-care providers and asking patients to search for personally held records. Persons whose records cannot be located should be considered susceptible and started or continued on the age-appropriate vaccine schedule.
- In settings in which written vaccination records are not accessible (e.g., sexually transmitted disease [STD] treatment facilities, human immunodeficiency virus [HIV] testing facilities, or correctional facilities), an oral history of completing a hepatitis B vaccine series can be used to defer hepatitis B vaccination. Persons in these settings who are uncertain about their vaccination status should be vaccinated. Other methods for assessing vaccination history (e.g., assuming a person received hepatitis B vaccine to comply with preschool or middle school entry requirements or participation in the U.S. military) might be considered, but such methods require further research before they can be recommended as reliable alternatives.
- Determining immunity from previous infection through serologic testing is an alternative to vaccination. However, using serologic testing to assess immunity from vaccination in persons with unknown or uncertain vaccination status can be problematic (see Prevacination Serologic Testing for Susceptibility).
- Persons who reside in the United States but were vaccinated in other countries should be considered fully vaccinated if they have written documentation of  $\geq 3$  doses of vaccine administered at recommended minimum intervals, including the final dose at age  $\geq 24$  weeks. If they were not vaccinated according to recommended minimum intervals, they should be revaccinated (see Minimum Dosing Intervals and Management of Persons Who Were Vaccinated Incorrectly). Persons without written documentation of full vaccination should receive doses to complete the age-appropriate vaccine series.

### Interrupted Vaccine Schedules

- When the hepatitis B vaccine schedule is interrupted, the vaccine series does not need to be restarted.
- If the series is interrupted after the first dose, the second dose should be administered as soon as possible, and the second and third doses should be separated by an interval of at least 8 weeks.
- If only the third dose has been delayed, it should be administered as soon as possible.

### Minimum Dosing Intervals and Management of Persons Who Were Vaccinated Incorrectly

- The third dose of vaccine must be administered at least 8 weeks after the second dose and should follow the first dose by at least 16 weeks; the minimum interval between the first and second doses is 4 weeks.
- Inadequate doses of hepatitis B vaccine (see Table 2) or doses received after a shorter-than-recommended dosing interval should be readministered, using the correct dosage or schedule.

### Accelerated Vaccine Schedules

- The Food and Drug Administration has not approved accelerated schedules in which hepatitis B vaccine is administered more than once in 1 month. If an accelerated schedule (e.g., doses at 0, 7, and 14 days) is used, the patient also should receive a booster dose at least 6 months after the start of the series to promote long-term immunity.

### Hemodialysis Patients and Other Immunocompromised Persons

- Hepatitis B vaccination is recommended for pre–end-stage renal disease patients before they become dialysis dependent and for peritoneal and home dialysis patients because they might require in-center hemodialysis.
- Higher hepatitis B vaccine doses are recommended for adult dialysis patients and other immunocompromised persons (see Table 2).
- Serologic testing of hemodialysis patients and other immunocompromised persons is recommended 1–2 months after administration of the final dose of the primary vaccine series to determine the need for revaccination (see Postvaccination Testing for Serologic Response). In addition, booster doses of vaccine might be needed (see Booster Doses).

### Prevaccination Serologic Testing for Susceptibility

- Vaccination of persons who are immune to hepatitis B virus (HBV) infection because of current or previous infection or vaccination does not increase the risk for adverse events. However, in adult populations that have expected high rates of previous HBV infection, prevaccination testing might reduce costs by avoiding vaccination of persons who are already immune (Box). Prevaccination testing is recommended for all foreign-born

**BOX. Method to determine cost-effectiveness of prevaccination screening for hepatitis B virus infection when the first vaccine dose is administered at the time of blood draw**

Prevaccination testing is cost effective when the cost of serologic testing is less than or equal to the cost of vaccinating persons who are already immune, as expressed by the formula

$$T \leq P1 \times [P2 + P2(P3)] \times v$$

where

T = cost of serologic testing (including cost of blood draw);

P1 = prevalence of previous infection;

P2 = percentage of recipients of first dose who actually receive a second dose;

P3 = percentage of recipients of doses 1 and 2 who receive dose 3;

[P2 + P2 (P3)] = average number of doses for a person starting the series; and

v = cost per dose of vaccine, including administrative costs.

persons (including immigrants, refugees, asylum seekers, and internationally adopted children) born in Africa, Asia, the Pacific Islands, and other regions with high endemicity of HBV infection (HBsAg prevalence of  $\geq 8\%$ ) (see Figure 4 and Box, Appendix C); for household, sex, and needle-sharing contacts of HBsAg-positive persons; and for HIV-infected persons (8). In addition, testing might be cost effective in adult populations with a prevalence of HBV infection of  $>20\%$  (e.g., injection-drug users, incarcerated persons, men who have sex with men; and persons born in countries with intermediate levels of endemic HBV infection [HBsAg prevalence of  $2\%–7\%$ ] [see Figure 4 and Box 2]). In a study conducted in correctional facilities, the cost of prevaccination testing was equivalent to vaccination without testing at a threshold prevalence of HBV infection of  $25\%$  (9).

- Prevaccination testing can be done with a single test (anti-HBc) or with a panel of tests (e.g., HBsAg and anti-HBs). The typical interpretation of HBV serologic markers has been described (see Table 1).
- When a single test is used, testing for anti-HBc is preferred because it identifies all persons with previous HBV infection, including persons with chronic HBV infection.
- If prevaccination testing for anti-HBs is used to identify immunity after previous HBV infection, HBsAg testing also must be performed to identify persons with chronic HBV infection. However, for persons who were vac-

nated previously or whose vaccination status is unknown, interpretation of anti-HBs results can be problematic. Postvaccination anti-HBs concentrations decline over time, and vaccine responders remain protected even when anti-HBs concentrations are no longer detectable; therefore, a negative anti-HBs result does not necessarily indicate lack of immunity in vaccinated persons. In addition, an anti-HBs-positive result can occur even for persons who received  $\geq 1$  dose of vaccine but did not complete the series. However, long-term protection has been demonstrated only for persons who have completed a licensed vaccination series and have ever had an anti-HBs concentration of  $\geq 10$  mIU/mL; persons with an anti-HBs-positive result but who did complete a vaccine schedule might not have long-term protection from HBV infection.

- Serologic testing should not be a barrier to vaccination of susceptible persons, especially in populations that are difficult to access. The first vaccine dose typically should be administered immediately after collection of the blood sample for serologic testing.

## Postvaccination Testing for Serologic Response

- Serologic testing for immunity is not necessary after routine vaccination of adults.
- Testing after vaccination is recommended only for the following persons whose subsequent clinical management depends on knowledge of their immune status:
  - Health-care workers and public safety workers at high risk for continued percutaneous or mucosal exposure to blood or body fluids (e.g., acupuncturists, dentists, dental hygienists, emergency medical technicians, first responders, laboratory technologists/technicians, nurses, nurse practitioners, phlebotomists, physicians, physician assistants, and students entering these professions), to determine the need for revaccination and to guide postexposure prophylaxis. Testing persons at low risk for continued mucosal or percutaneous exposure to blood or body fluids (e.g., public safety workers and health-care workers without direct patient contact) is not likely to be cost effective. Health-care and public safety workers who have written documentation of a complete vaccine series but who have never had postvaccination testing do not need serologic testing for anti-HBs unless they have a percutaneous or mucosal exposure to blood or body fluids (10).
  - Chronic hemodialysis patients, HIV-infected persons, and other immunocompromised persons (e.g., hematopoietic stem-cell transplant recipients or per-

sons receiving chemotherapy), to determine the need for revaccination and the type of follow-up testing.

- Sex partners of HBsAg-positive persons, to determine the need for revaccination and for other methods of protection against HBV infection.
- Testing should be performed 1–2 months after administration of the last dose of the vaccine series using a method that allows determination of a protective concentration of anti-HBs ( $\geq 10$  mIU/mL).
- Persons found to have anti-HBs concentrations of  $\geq 10$  mIU/mL after the primary vaccine series are considered to be immune.
  - Immunocompetent persons have long-term protection and do not need further periodic testing to assess anti-HBs levels.
  - Immunocompromised persons might need annual testing to assess anti-HBs concentrations (see Booster Doses).
- Persons found to have anti-HBs concentrations of  $< 10$  mIU/mL after the primary vaccine series should be revaccinated. Administration of 3 doses on an appropriate schedule (see Box 5), followed by anti-HBs testing 1–2 months after the third dose, usually is more practical than serologic testing after 1 or more doses of vaccine.
- Persons who do not have a protective concentration of anti-HBs after revaccination should be tested for HBsAg.
  - If the HBsAg test result is positive, the person should receive appropriate management, and any household, sex, or needle-sharing contacts should be identified and vaccinated (see Appendix C).
  - Persons who test negative for HBsAg should be considered susceptible to HBV infection and should be counseled about precautions to prevent HBV infection and the need to obtain HBIG postexposure prophylaxis for any known or likely parenteral exposure to HBsAg-positive blood (10).

## Booster Doses

- Booster doses are not recommended for persons with normal immune status who were vaccinated as infants, children, adolescents, or adults. Serologic testing is not recommended to assess antibody concentrations in any

age group, except in certain circumstances (see Postvaccination Testing for Serologic Response).

- For hemodialysis patients, the need for booster doses should be assessed by annual anti-HBs testing. A booster dose should be administered when anti-HBs levels decline to  $< 10$  mIU/mL.
- For other immunocompromised persons (e.g., HIV-infected persons, hematopoietic stem-cell transplant recipients, and persons receiving chemotherapy), the need for booster doses has not been determined. When anti-HBs levels decline to  $< 10$  mIU/mL, annual anti-HBs testing and booster doses should be considered for persons with an ongoing risk for exposure.

## References

1. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. *Vaccine* 1989;7:425–30.
2. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. *JAMA* 1985;254:3187–9.
3. CDC. Suboptimal response to hepatitis B vaccine given by injection into the buttock. *MMWR* 1985;34:105–8, 113.
4. Ukena T, Esber H, Bessette R, Parks T, Crocker B, Shaw FE Jr. Site of injection and response to hepatitis B vaccine. *N Engl J Med* 1985; 313:579–80.
5. Bryan JP, Sjogren MH, MacArthy P, Cox E, Legters LJ, Perine PL. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. *Vaccine* 1992;10:33–8.
6. Coberly JS, Townsend T, Repke J, Fields H, Margolis H, Halsey NA. Suboptimal response following intradermal hepatitis B vaccine in infants. *Vaccine* 1994;12:984–7.
7. CDC. General recommendations on immunization 2006: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. In press.
8. CDC. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. *MMWR* 2004;53(No. RR-15).
9. CDC. Hepatitis B vaccination of inmates in correctional facilities—Texas, 2000–2002. *MMWR* 2004;53:681–3.
10. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. *MMWR* 2001; 50(No. RR-11).

## Appendix B

### Postexposure Prophylaxis to Prevent Hepatitis B Virus Infection

This appendix provides guidelines for management of persons with nonoccupational exposure to hepatitis B virus (HBV) through a discrete, identifiable exposure to blood or body fluids (Table). Guidelines for postexposure prophylaxis of occupational exposures have been published separately (1) and are intended for use in settings in which postvaccination testing is recommended for certain employees (see Appendix A, Postvaccination Testing for Serologic Response) and in which programs are available to implement testing and follow-up algorithms. Recommendations for management of infants born to hepatitis B surface antigen (HBsAg)-positive mothers also have been published separately (2).

#### HBsAg-Positive Exposure Source

- Persons who have written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing should receive a single vaccine booster dose.
- Persons who are in the process of being vaccinated but who have not completed the vaccine series should receive

the appropriate dose of hepatitis B immune globulin (HBIG) and should complete the vaccine series.

- Unvaccinated persons should receive both HBIG and hepatitis B vaccine as soon as possible after exposure (preferably within 24 hours). Hepatitis B vaccine may be administered simultaneously with HBIG in a separate injection site. The hepatitis B vaccine series should be completed in accordance with the age-appropriate vaccine dose and schedule (see Table 2 and Box 5).

#### Exposure Source with Unknown HBsAg Status

- Persons with written documentation of a complete hepatitis B vaccine series require no further treatment.
- Persons who are not fully vaccinated should complete the vaccine series.
- Unvaccinated persons should receive the hepatitis B vaccine series with the first dose administered as soon as possible after exposure, preferably within 24 hours. The

**TABLE. Guidelines for postexposure prophylaxis\* of persons with nonoccupational exposures† to blood or body fluids that contain blood, by exposure type and vaccination status**

| Exposure  | Treatment  |   |
|---|--|---|
|   | Unvaccinated person§   | Previously vaccinated person¶               |
| <b>HBsAg** -positive source</b>   |  |   |
| Percutaneous (e.g., bite or needlestick) or mucosal exposure to HBsAg-positive blood or body fluids   | Administer hepatitis B vaccine series and hepatitis B immune globulin (HBIG) | Administer hepatitis B vaccine booster dose |
| Sex or needle-sharing contact of an HBsAg-positive person   | Administer hepatitis B vaccine series and HBIG                               | Administer hepatitis B vaccine booster dose |
| Victim of sexual assault/abuse by a perpetrator who is HBsAg positive   | Administer hepatitis B vaccine series and HBIG                               | Administer hepatitis B vaccine booster dose |
| <b>Source with unknown HBsAg status</b>   |  |   |
| Victim of sexual assault/abuse by a perpetrator with unknown HBsAg status   | Administer hepatitis B vaccine series  | No treatment                                |
| Percutaneous (e.g., bite or needlestick) or mucosal exposure to potentially infectious blood or body fluids from a source with unknown HBsAg status | Administer hepatitis B vaccine series  | No treatment                                |
| Sex or needle-sharing contact of person with unknown HBsAg status   | Administer hepatitis B vaccine series  | No treatment                                |

\* When indicated, immunoprophylaxis should be initiated as soon as possible, preferably within 24 hours. Studies are limited on the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures or 14 days for sexual exposures. The hepatitis B vaccine series should be completed.

† These guidelines apply to nonoccupational exposures. Guidelines for management of occupational exposures have been published separately (1) and also can be used for management of nonoccupational exposures, if feasible.

§ A person who is in the process of being vaccinated but who has not completed the vaccine series should complete the series and receive treatment as indicated.

¶ A person who has written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing.

\*\* Hepatitis B surface antigen.

vaccine series should be completed in accordance with the age-appropriate dose and schedule (see Table 2 and Box 5).

**References**

1. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 50(No. RR-11).
2. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR 2005;54(No. RR-16).

## Appendix C

### Identification and Management of Hepatitis B Surface Antigen (HBsAg)–Positive Persons

Persons with chronic hepatitis B virus (HBV) infection are at high risk for chronic liver disease and are a major reservoir of HBV infection. Foreign-born populations from Africa, Asia, and the Pacific Islands have high rates of chronic HBV infection (i.e., HBsAg prevalence of  $\geq 8\%$ ). During delivery of recommended hepatitis B vaccination services (e.g., HBsAg screening of pregnant women and serologic testing to assess susceptibility), vaccination providers will identify persons who are HBsAg positive. These persons require counseling and medical management for chronic HBV infection to reduce their risk for chronic liver disease. Their susceptible household, sex, and needle-sharing contacts also should be vaccinated against hepatitis B.

Extending screening, referral, and contact vaccination services to persons identified as HBsAg positive can help prevent serious sequelae in persons with chronic infection and enhance vaccination strategies to eliminate HBV transmission. This appendix provides guidance for vaccination providers concerning identification and management of persons with chronic HBV infection. These guidelines are not intended to represent a comprehensive prevention program for persons with chronic infection.

#### Identification of Persons Who Are Potentially HBsAg Positive

- All foreign-born persons (including immigrants, refugees, asylum seekers, and internationally adopted children) from Africa, Asia, the Pacific Islands, and other regions with high endemicity of HBV infection (Box) should be tested for HBsAg, regardless of vaccination status.
  - For all persons born in countries in which HBV is highly endemic who are applying for permanent U.S. residence, HBsAg screening and appropriate follow-up on the basis of HBsAg test results should be included as part of the required overseas premigration and domestic adjustment-of-visa status medical examination process; information about this process is available at <http://www.cdc.gov/ncidod/dq/health.htm>. HBsAg-positive persons should be considered eligible for migration and adjustment-of-visa status and counseled and recommended for follow-up medical evaluation and management in U.S. resettlement communities.
  - In all settings that provide health care, providers should identify persons born in countries in which HBV infec-

#### BOX. Geographic regions\* with high<sup>†</sup> hepatitis B virus endemicity

**Africa:** all countries except Algeria, Djibouti, Egypt, Libya, Morocco, and Tunisia

**Southeast Asia:** all countries except Malaysia

**East Asia:** China, Hong Kong, Mongolia, North Korea, South Korea, and Taiwan

**Australia and South Pacific:** all countries except Australia, Guam, and New Zealand

**Middle East:** Jordan and Saudi Arabia

**Eastern Europe and Northern Asia:** Albania, Armenia, Azerbaijan, Bulgaria, Croatia, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan

**Western Europe:** Malta and indigenous populations in Greenland

**North America:** Alaska Natives and indigenous populations in Northern Canada

**South America:** Amazonian areas of Bolivia, Brazil, Columbia, Peru, and Venezuela

**Caribbean:** Turks and Caicos

\* A complete list of countries in each region is available at <http://www.cdc.gov/travel/destinat.htm>.

<sup>†</sup> Hepatitis B surface antigen prevalence of  $\geq 8\%$ .

tion is highly endemic and provide HBsAg testing and follow-up. Retesting of persons who were tested for HBsAg in other countries should be considered.

- Other persons who should be tested for HBsAg as part of vaccination services include
  - all pregnant women (1);
  - persons who receive prevaccination testing for susceptibility and who test positive for anti-HBc (see Appendix A, Prevaccination Serologic Testing for Susceptibility);
  - hemodialysis patients; and
  - nonresponders to vaccination (see Appendix A, Postvaccination Testing for Serologic Response).

#### Management of Persons Identified as HBsAg Positive

- All HBsAg-positive laboratory results should be reported to the state or local health department, in accordance with

state requirements for reporting of chronic HBV infection; information about state requirements is available at <http://www.cste.org/NNDSSSurvey/2004NNDSS/nndssstatechrreporcond2005.asp>.

- HBsAg-positive persons should be referred for evaluation to a physician experienced in the management of chronic liver disease; a directory of liver specialists is available at [http://www.hepb.org/resources/other\\_links\\_physician.htm](http://www.hepb.org/resources/other_links_physician.htm). Certain patients with chronic HBV infection will benefit from early intervention with antiviral treatment, management of factors that can contribute to disease progression, or screening to detect hepatocellular carcinoma at an early stage.
- Household, sex, and needle-sharing contacts of HBsAg-positive persons should be identified. Unvaccinated sex partners and household and needle-sharing contacts should be tested for susceptibility to HBV infection (see Appendix A, Prevacination Serologic Testing for Susceptibility) and should receive the first dose of hepatitis B vaccine immediately after collection of blood for serologic testing. Susceptible persons should complete the vaccine series using an age-appropriate vaccine dose and schedule (see Table 2 and Box 5). Persons who are not fully vaccinated should complete the vaccine series.
- Sex partners of HBsAg-positive persons should be counseled to use methods (e.g., condoms) to protect themselves from sexual exposure to infectious body fluids (e.g., semen or vaginal secretions) unless they have been demonstrated to be immune after vaccination (i.e., antibody to HBsAg concentrations of  $\geq 10$  mIU/mL) or previously infected (anti-HBc positive). Partners should be made aware that use of condoms and other prevention methods might reduce their risks for human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs).
- To prevent or reduce the risk for transmission to others, HBsAg-positive persons should be advised concerning the risks for
  - perinatal transmission to infants born to HBsAg-positive women and the need for such infants to receive hepatitis B vaccine beginning at birth (1) and
  - transmission to household, sex, and needle-sharing contacts and the need for such contacts to receive hepatitis B vaccine.
- HBsAg-positive persons should also be advised to
  - notify their sex partners about their status;
  - use methods (e.g., condoms) to protect nonimmune sex partners from acquiring HBV infection from sexual activity until the sex partners can be vaccinated and

their immunity documented (persons should be made aware that use of condoms and other prevention methods might reduce their risks for HIV and other STDs);

- cover cuts and skin lesions to prevent spread through infectious secretions or blood;
- refrain from donating blood, plasma, tissue, or semen (organs may be donated to HBV-immune or chronically infected persons needing a transplant; decisions about organ donation should be made on an individual basis); and
- refrain from sharing household articles (e.g., toothbrushes, razors, or personal injection equipment) that could become contaminated with blood.

- To protect the liver from further harm, HBsAg-positive persons should be advised to
  - avoid or limit alcohol consumption because of the effects of alcohol on the liver;
  - refrain from taking any new medicines, including over-the-counter and herbal medicines, without consulting with their health-care provider; and
  - obtain vaccination against hepatitis A if chronic liver disease is present (2).
- When seeking medical or dental care, HBsAg-positive persons should be advised to inform those responsible for their care of their HBsAg status so that they can be evaluated and their care managed appropriately.
- Other counseling messages include the following:
  - HBV is not spread by breastfeeding, kissing, hugging, coughing, ingesting food or water, sharing eating utensils or drinking glasses, or casual contact.
  - Persons should not be excluded from work, school, play, child care, or other settings on the basis of their HBsAg status, unless they are prone to biting (3).
  - Involvement with a support group might help patients cope with chronic HBV infection. Information about support groups is available at <http://www.hepprograms.org/support/hepb.asp> and [http://www.hepb.org/patients/support\\_groups.htm](http://www.hepb.org/patients/support_groups.htm).

### References

1. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. *MMWR* 2005;54(No. RR-16).
2. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(No. RR-7).
3. Shapiro CN, McCaig LF, Gensheimer KF, et al. Hepatitis B virus transmission between children in day care. *Pediatr Infect Dis J* 1989;8:870–5.



# MMWR™

## Morbidity and Mortality Weekly Report

Recommendations and Reports

December 8, 2006 / Vol. 55 / No. RR-16

### Continuing Education Activity Sponsored by CDC

#### A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults

**EXPIRATION — December 8, 2009**

You must complete and return the response form electronically or by mail by **December 8, 2009**, to receive continuing education credit. If you answer all of the questions, you will receive an award letter for 3.0 hours Continuing Medical Education (CME) credit; 0.25 Continuing Education Units (CEUs); or

3.0 contact hours Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are charged for participating in this continuing education activity.

### INSTRUCTIONS

#### By Internet

1. Read this *MMWR* (Vol. 55, RR-16), which contains the correct answers to the questions beginning on the next page.
2. Go to the *MMWR* Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
6. Submit your answers no later than **December 8, 2009**.
7. Immediately print your Certificate of Completion for your records.

#### By Mail or Fax

1. Read this *MMWR* (Vol. 55, RR-16), which contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive continuing education credit, you must answer all of the questions. Questions with more than one correct answer will instruct you to "Indicate all that apply."
5. Sign and date the response form or a photocopy of the form and send no later than **December 8, 2009**, to  
Fax: 404-498-2388  
Mail: MMWR CE Credit  
Coordinating Center for Health Information and Service, MS E-90  
Centers for Disease Control and Prevention  
1600 Clifton Rd, N.E.  
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.

### ACCREDITATION

**Continuing Medical Education (CME).** CDC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CDC designates this educational activity for a maximum of 3.0 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**Continuing Education Unit (CEU).** CDC has been approved as an authorized provider of continuing education and training programs by the International Association for Continuing Education and Training. CDC will award 0.25 continuing education units to participants who successfully complete this activity.

**Continuing Nursing Education (CNE).** This activity for 3.0 contact hours is provided by CDC, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

## Goal and Objectives

This report updates the immunization strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report includes new recommendations regarding which adults should receive hepatitis B vaccine and provides implementation strategies to ensure that those adults are vaccinated. The goal of the report is to provide strategies for health-care professionals to increase hepatitis B vaccination coverage among adults at risk for HBV infection. Strategies are directed toward settings in which a high proportion of persons have risks for HBV infection and primary care and specialty medical settings in which persons at risk for HBV infection receive care. Upon completion of this educational activity, the reader should be able to 1) identify adults who are recommended to receive hepatitis B vaccination, 2) identify settings in which a high proportion of persons are likely to be at risk for HBV infection, 3) identify components of a successful adult hepatitis B vaccination program, 4) identify strategies to increase vaccination coverage among adults at risk for HBV infection, 5) describe practices that should be implemented in settings in which adults receive hepatitis B vaccine, and 6) describe adult vaccination schedules.

**To receive continuing education credit, please answer all of the following questions.**

1. **In which settings is universal hepatitis B vaccination recommended because of the high proportion of adults with behavioral risk factors for HBV infection?**
  - A. Sexually transmitted disease and human immunodeficiency virus (STD/HIV) testing and treatment facilities.
  - B. Drug-abuse treatment and prevention settings.
  - C. Health-care settings targeting services to men who have sex with men (MSM).
  - D. Correctional facilities.
  - E. Hospitals.
2. **The Advisory Committee on Immunization Practices (ACIP) recommends standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine services in primary care and specialty medical settings.**
  - A. True.
  - B. False.
3. **Which of the following practices should be implemented in primary care and specialty medical settings to ensure vaccination of adults at risk for HBV infection? (Indicate all that apply.)**
  - A. Provide information to all adults regarding the benefits of hepatitis B vaccination, including the risk factors for HBV infection and persons for whom vaccination is recommended.
  - B. Help adults assess their need for vaccination by obtaining a history that emphasizes risks for sexual transmission and percutaneous or mucosal exposure to blood.
  - C. Provide hepatitis B vaccine to persons who report risk factors for HBV infection.
  - D. Request that adults acknowledge a specific factor for HBV infection before offering hepatitis B vaccine.
4. **Which of the following are components of a successful adult hepatitis B vaccination program? (Indicate all that apply.)**
  - A. Protocols and standing orders.
  - B. Protected patient confidentiality.
  - C. Trained and knowledgeable staff.
  - D. Funding for vaccine.
  - E. Billing and reimbursement mechanisms.
5. **Which of the following persons are recommended to receive hepatitis B vaccine because they have a risk factor for HBV infection? (Indicate all that apply.)**
  - A. Sexually active persons who are not in a long-term, mutually monogamous relationship.
  - B. Injection-drug users.
  - C. MSM.
  - D. Persons who live in a household with a person who is hepatitis B surface antigen (HBsAg)-positive.
  - E. Persons seeking treatment for an STD.
  - F. Pregnant women.
6. **Which of the following statements regarding hepatitis B vaccination are true? (Indicate all that apply.)**
  - A. Hepatitis B vaccine is available as a single-antigen formulation only.
  - B. Primary vaccination against hepatitis B consists of 3 doses administered at 0, 1, and 6 months.
  - C. Increasing the interval between the first 2 doses has little effect on immunogenicity or final antibody concentration.
  - D. Differences in immunogenicity have been observed when hepatitis B vaccines produced by different manufacturers are used to complete the vaccine series.
  - E. Routine vaccination of adults should be followed by postvaccination testing to determine serologic response.
7. **Which of the following statements regarding immune memory for hepatitis B are true? (Indicate all that apply.)**
  - A. Antibody to HBsAg (anti-HBs) is the only easily measurable correlate of vaccine-induced protection.
  - B. After primary vaccination with hepatitis B vaccine, anti-HBs concentrations decline rapidly within the first year.
  - C. When anti-HBs concentrations decline to <10 mIU/mL, all vaccinated persons should receive a booster dose of hepatitis B vaccine.
  - D. A booster dose of hepatitis B vaccine is recommended 10 years after the 3rd dose of vaccine was received.
8. **Which of the following statements regarding hepatitis B immune globulin (HBIG) are true? (Indicate all that apply.)**
  - A. HBIG provides temporary protection when administered in standard doses.
  - B. HBIG typically is used instead of hepatitis B vaccine for postexposure immunoprophylaxis to prevent HBV infection.
  - C. No evidence exists that HBV, hepatitis C virus, or HIV have ever been transmitted by HBIG in the United States.
  - D. HBIG administered alone is the primary means of protection after an HBV exposure for nonresponders to hepatitis B vaccination.
9. **Postvaccination testing is recommended for which of the following populations? (Indicate all that apply.)**
  - A. Certain health-care and public safety workers.
  - B. Chronic hemodialysis patients.
  - C. HIV-infected persons.
  - D. HCV-infected persons.
  - E. Sex partners of HBsAg-positive persons.
10. **Which best describes your professional activities?**
  - A. Physician.
  - B. Nurse.
  - C. Health educator.
  - D. Office staff.
  - E. Other.
11. **I plan to use these recommendations as the basis for... (Indicate all that apply.)**
  - A. health education materials.
  - B. insurance reimbursement policies.
  - C. local practice guidelines.
  - D. public policy.
  - E. other.

12. Overall, the length of the journal report was...
- A. much too long.
  - B. a little too long.
  - C. just right.
  - D. a little too short.
  - E. much too short.
13. After reading this report, I am confident I can identify adults who are recommended to receive hepatitis B vaccination.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.
14. After reading this report, I am confident I can identify settings in which a high proportion of persons are likely to be at risk for HBV infection.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.
15. After reading this report, I am confident I can identify components of a successful adult hepatitis B vaccination program.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.

16. After reading this report, I am confident I can identify strategies to increase vaccination coverage among adults at risk for HBV infection.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.
17. After reading this report, I am confident I can describe practices that should be implemented in settings in which adults receive hepatitis B vaccine.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.
18. After reading this report, I am confident I can describe adult vaccination schedules.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.
19. The learning outcomes (objectives) were relevant to the goals of this report.
- A. Strongly agree.
  - B. Agree.
  - C. Undecided.
  - D. Disagree.
  - E. Strongly disagree.

(Continued on pg CE-4)

**MMWR Response Form for Continuing Education Credit  
December 8, 2006/Vol. 55/No. RR-16**

**A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults**

To receive continuing education credit, you must

1. provide your contact information (please print or type);
2. indicate your choice of CME, CME for nonphysicians, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by December 8, 2009.

Failure to complete these items can result in a delay or rejection of your application for continuing education credit.

Detach or photocopy.

Check One

Last Name (print or type) \_\_\_\_\_ First Name \_\_\_\_\_

Street Address or P.O. Box \_\_\_\_\_

Apartment \_\_\_\_\_ or \_\_\_\_\_ Suite \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ ZIP Code \_\_\_\_\_

Phone Number \_\_\_\_\_ Fax Number \_\_\_\_\_

E-Mail Address \_\_\_\_\_

CME Credit  
 CME for nonphysicians Credit  
 CEU Credit  
 CNE Credit

Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to receive continuing education credit!

|  |   |
|--|---|
| 1. [ ] A [ ] B [ ] C [ ] D [ ] E       | 15. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 2. [ ] A [ ] B [ ] C [ ] D [ ] E       | 16. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 3. [ ] A [ ] B [ ] C [ ] D [ ] E       | 17. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 4. [ ] A [ ] B [ ] C [ ] D [ ] E       | 18. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 5. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F | 19. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 6. [ ] A [ ] B [ ] C [ ] D [ ] E       | 20. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 7. [ ] A [ ] B [ ] C [ ] D [ ] E       | 21. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 8. [ ] A [ ] B [ ] C [ ] D [ ] E       | 22. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 9. [ ] A [ ] B [ ] C [ ] D [ ] E       | 23. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 10. [ ] A [ ] B [ ] C [ ] D [ ] E      | 24. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 11. [ ] A [ ] B [ ] C [ ] D [ ] E      | 25. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 12. [ ] A [ ] B [ ] C [ ] D [ ] E      | 26. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 13. [ ] A [ ] B [ ] C [ ] D [ ] E      | 27. [ ] A [ ] B [ ] C [ ] D [ ] E       |
| 14. [ ] A [ ] B [ ] C [ ] D [ ] E      | 28. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F |

Signature \_\_\_\_\_

Date I Completed Exam \_\_\_\_\_

20. The instructional strategies used in this report (text, tables, figures, boxes, and appendices) helped me learn the material.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
21. The content was appropriate given the stated objectives of the report.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
22. The content expert(s) demonstrated expertise in the subject matter.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
23. Overall, the quality of the journal report was excellent.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
24. These recommendations will improve the quality of my practice.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
25. The availability of continuing education credit influenced my decision to read this report.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
26. The *MMWR* format was conducive to learning this content.
- Strongly agree.
  - Agree.
  - Undecided.
  - Disagree.
  - Strongly disagree.
27. Do you feel this course was commercially biased? (*Indicate yes or no; if yes, please explain in the space provided.*)
- Yes.
  - No.
28. How did you learn about the continuing education activity?
- Internet.
  - Advertisement (e.g., fact sheet, *MMWR* cover, newsletter, or journal).
  - Coworker/supervisor.
  - Conference presentation.
  - MMWR* subscription.
  - Other.

Correct answers for questions 1-9.  
1. A, B, C, and D. 2. A, 3. A, B, and C. 4. A, B, C, D, and E. 5. A, B, C, D, and E. 6. B and C. 7. A and B. 8. A, C, and D. 9. A, B, C, and E.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to [www.mmwrq@cdc.gov](mailto:www.mmwrq@cdc.gov).

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.